US6348201B2 - External composition for skin comprising sphingoglycolipid - Google Patents

External composition for skin comprising sphingoglycolipid Download PDF

Info

Publication number
US6348201B2
US6348201B2 US09/084,394 US8439498A US6348201B2 US 6348201 B2 US6348201 B2 US 6348201B2 US 8439498 A US8439498 A US 8439498A US 6348201 B2 US6348201 B2 US 6348201B2
Authority
US
United States
Prior art keywords
skin
external composition
cream
preparing
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/084,394
Other versions
US20020006414A1 (en
Inventor
Katsumi Murata
Takashi Nozawa
Hisako Hara
Michiki Asai
Sachio Wakayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kikkoman Biochemifa Co
Original Assignee
Kibun Food Chemifa KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP14177097A external-priority patent/JPH10327853A/en
Priority claimed from JP9141771A external-priority patent/JPH10330273A/en
Priority claimed from JP00996398A external-priority patent/JP3483448B2/en
Priority claimed from JP6174998A external-priority patent/JP3504137B2/en
Application filed by Kibun Food Chemifa KK filed Critical Kibun Food Chemifa KK
Assigned to KIBUN FOOD CHEMIFA CO., LTD. reassignment KIBUN FOOD CHEMIFA CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASAI, MICHIKI, HARA, HISAKO, MURATA, KATSUMI, NOZAWA, TAKASHI, WAKAYAMA, SACHIO
Priority to US10/012,510 priority Critical patent/US6514744B2/en
Publication of US20020006414A1 publication Critical patent/US20020006414A1/en
Publication of US6348201B2 publication Critical patent/US6348201B2/en
Application granted granted Critical
Assigned to KIKKOMAN BIOCHEMIFA COMPANY reassignment KIKKOMAN BIOCHEMIFA COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FOODCHEMIFA CO., LTD.
Assigned to FOODCHEMIFA CO., LTD. reassignment FOODCHEMIFA CO., LTD. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: KIBUN FOOD CHEMIFA CO., LTD.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0212Face masks
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/87Application Devices; Containers; Packaging
    • A61K2800/872Pencils; Crayons; Felt-tip pens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02Preparations containing skin colorants, e.g. pigments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02Preparations containing skin colorants, e.g. pigments
    • A61Q1/04Preparations containing skin colorants, e.g. pigments for lips
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02Preparations containing skin colorants, e.g. pigments
    • A61Q1/04Preparations containing skin colorants, e.g. pigments for lips
    • A61Q1/06Lipsticks
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02Preparations containing skin colorants, e.g. pigments
    • A61Q1/08Preparations containing skin colorants, e.g. pigments for cheeks, e.g. rouge
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02Preparations containing skin colorants, e.g. pigments
    • A61Q1/10Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/10Washing or bathing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/02Preparations for cleaning the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/06Preparations for styling the hair, e.g. by temporary shaping or colouring
    • A61Q5/065Preparations for temporary colouring the hair, e.g. direct dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q9/00Preparations for removing hair or for aiding hair removal
    • A61Q9/02Shaving preparations
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales

Definitions

  • This invention relates to external compositions for skin comprising sphingoglycolipid available as cosmetic and medicine.
  • the external compositions for skin of the present invention have a potent moisturizing effect and preventive effect against skin roughness.
  • Skin roughness is caused by losing moisture from the skin surface during dry weather or cleansing. Miscellaneous chemical substances present in modern society can contact skin to inhibit skin functions, which may also result in skin roughness due to depression of lipid secretion ability. It is thus expected to provide external compositions for skin having an excellent moisturizing effect and capable of preventing skin roughness before it occurs.
  • JP-A-H1-242690, H2-48520, H4-159203 and JP-B-H6-80007 describe that sphingoglycolipid has a skin moisturizing effect. Structures and compositions of the sphingoglycolipids appears in these patent specifications are, however, not clearly disclosed.
  • JP-A-H6-157283 describes a moisturizing external cutaneous cosmetic containing, as its one component, a sphingoglycolipid represented by a specific general formula.
  • the sugar portion of this general formula is, however, expressed simply as a saccharide residue without mentioning its details.
  • JP-A-S61-286307 clearly specifies a sphingoglycolipid having a moisturizing effect.
  • This patent describes that ganglioside has skin moisturizing and emollient effects and discloses skin cosmetics containing such ganglioside or its salts.
  • Ganglioside refers to a sphingoglycolipid typically containing neutral sugar, amino sugar and sialic acid.
  • Cerebroside refers to a sphingoglycolipid containing 1 mol each of fatty acid, sphingosine base and neutral sugar (galactose or glucose).
  • an object of the present invention to provide an external composition for skin comprising Sphingomonas strain extract having an excellent moisturizing effect and preventive effect against skin roughness. It is another object of the present invention to provide an external composition for skin comprising an extract with a color lighter than that of the previous extracts from Sphingomonas strains. It is another object of the present invention to provide Sphingomonas strains capable of producing such extract with a lighter color. It is still another object of the present invention to identify structures of sphingoglycolipids having potent moisturizing and skin roughness preventive effects and to provide an external composition for skin comprising such glycolipids.
  • the first aspect of the invention relates to providing an external composition for skin obtained by washing Sphingomonas strain with acetone, and extracting the resultants with alcohol or alcohol-water mixture.
  • Preferable extracting solutions are methanol, propanol-water mixture or butanol-water mixture.
  • Propanol content in propanol-water mixture is preferably 75 wt % or below.
  • Butanol content in butanol-water mixture is preferably 95 wt % or below, and more preferably 85 to 95 wt %, both ends inclusive.
  • the second aspect of the invention relates to provide an external composition for skin comprising an extract obtained from white bacteria of the genus Sphingomonas, in particular from Sphingomonas paucimobilis.
  • Preferable white bacteria include Sphingomonas paucimobilis KFC-W-1; deposition Nos. FERM P-16238 and BP-6368), Sphingomonas paucimobilis MK-253W; deposition Nos. FERM P-16693 and BP-6369), Sphingomonas paucimobilis MK-254W; deposition No. FERM P-16694 and BP-6370) and Sphingomonas paucimobilis MK-332W; deposition No. FERM P-16695 and BP-6371).
  • the third aspect of the invention relates to an external composition for skin comprising a sphingoglycolipid represented by a formula shown below:
  • R 1 represents a sugar portion consisting of a single uronic acid or one to four hexoses selected from a group consisting of uronic acid, glucosamine, galactose and mannose;
  • R 2 represents an alkyl group which may have a cycloalkyl group, an alkenyl group or an alkynyl group;
  • R 3 represents an alkyl group; these alkyl, alkenyl and alkynyl groups being straight or branched, and substituted or unsubstituted.
  • R 1 preferably consists of three to four hexoses. More preferably, R 1 is any one of a four-hexose sugar portion consisting of uronic acid, glucosamine, galactose and mannose; a three-hexose sugar portion consisting of uronic acid, glucosamine, and galactose; or a two-hexose sugar portion consisting of uronic acid and galactose. Still more preferably, R 1 is represented by any one of the following formulae:
  • R 2 preferably has 15 to 25 carbon atoms, and more preferably has any one of the following structures:
  • R 3 is preferably a substituted or unsubstituted straight alkyl group having 10 to 20 carbon atoms, and more preferably a straight alkyl group having 10 carbon atoms.
  • the external composition for skin of the invention is available as for example toilet soap, shampoo, cleansing foam, rinse, eye cream, eye shadow, cream or milky lotion, toilet lotion, perfume, face powder, facial oil, hair-care cosmetics, hair dye, jelly fragrance, powder, pack, shaving cream, shaving lotion, suntan oil, anti-suntan oil, suntan lotion, sun-screening lotion, suntan cream, sun-screening cream, foundation, powdery fragrance, cheek rouge, mascara, eyebrow pencil, nail cream, nail enamel, nail enamel remover, hair cleaner, bath cosmetics, lipstick, lip cream, eyeliner, toothpaste, deodorant agent, eau de cologne, hair tonic, hair restorer, ointment, wet pack, medicated lip cream or anti-atopic agent.
  • toilet soap for example toilet soap, shampoo, cleansing foam, rinse, eye cream, eye shadow, cream or milky lotion
  • toilet lotion perfume, face powder, facial oil, hair-care cosmetics, hair dye, jelly fragrance, powder, pack, shaving cream, shaving lotion, suntan oil, anti-suntan oil
  • the external composition for skin of the invention can contain at least one additive selected from a group consisting of whitening agent, surfactant, dye, perfumery, aseptic agent, pigment, mildewproof agent, antioxidant, UV absorber, infrared absorber, fluorescent material, metal ion blocker, binder, filler, antiphlogistic, circulation accelerator, cell activator and antibiotic.
  • An external composition for skin according to the first aspect of the invention comprises an extract obtained by washing Sphingomonas strain with acetone and successive extraction with alcohol or alcohol-water mixture.
  • Strains applicable to the present invention belong to the genus Sphingomonas. Strains in the genus Sphingomonas are known for their ability to produce various components including sphingoglycolipid. Any strain is allowable for the present invention provided that it belongs to genus Sphingomonas. Thus any strain in the classifications of Sphingomonas paucimobilis, Sphingomonas capsulata, or Sphingomonas adhaesiva is available.
  • Sphingomonas paucimobilis FERM BP-3631 Sphingomonas paucimobilis FERM BP-3632, Sphingomonas paucimobilis FERM BP-3633, Sphingomonas paucimobilis FERM BP-3634, Sphingomonas capsulate FERM BP-3709 and Sphingomonas adhaesiva FERM BP-3710
  • Sphingomonas paucimobilis FERM BP-3631 Sphingomonas paucimobilis FERM BP-3632, Sphingomonas paucimobilis FERM BP-3633, Sphingomonas paucimobilis FERM BP-3634, Sphingomonas capsulate FERM BP-3709 and Sphingomonas adhaesiva FERM BP-3710
  • the strain can be used either singly or in combination with other strain. Combination and mixing ratio of a plurality of strains is not limited.
  • the strain of genus Sphingomonas is first treated with acetone to thoroughly dewater the bacterial body, then the bacterial body is separated by a method, such as filtration.
  • Acetone is most preferably used as a single solvent, but its mixtures with water-base solvent are also allowable.
  • Addition volume of acetone is set between 0.1 to 1000 liters per 1 kg of wet fungus body, and more preferably between 1 to 10 liters.
  • the contents of the bacterial body is thoroughly brought into contact with acetone. It is also recommendable to apply physical force to the bacterial body to raise the contact efficiency.
  • a contact duration As far as water in the bacterial body is successfully removed. Generally the duration is set to 20 seconds to 2 hours according to extent of the physical stress. After that the bacterial body is separated from the acetone solution by, for example, filtration.
  • Alcohol used here is selected from hydrocarbon compounds having a hydroxyl group, and preferably from alkanol having 1 to 8 carbon atoms.
  • preferable ones include methanol, propanol and butanol, where methanol excels the others.
  • Structural isomers of propanol and butanol are also available, where n-propanol, isopropanol, and n-butanol are recommended.
  • propanol-water mixture and butanol-water mixture are preferable.
  • Propanol content in propanol-water mixture is preferably set not higher than 90%, and more preferably not higher than 75%.
  • Butanol content in butanol-water mixture is preferably set not higher than 95%, and more preferably between 80 to 95%.
  • Extraction using these solvents can comply with a method common in this technical field. For example, extraction is carried out once or repeated several times using approx. 1 to 50 liters of solvent per 1 kg of wet bacterial body.
  • Obtained extract is then distilled by a known method to remove the solvent to yield a residual syrup. Drying this residual syrup will result in a solid composition. It is also possible to obtain the solid composition by adding acetone to the residual syrup and by collecting the resultant precipitate by filtration or other methods.
  • sphingoglycolipid composition possesses excellent moisturizing and skin roughness preventing effects and is confirmed that it can provide appropriate moisture to skin surface to retain its smoothness. Such effects are much more superior to those of ganglioside or galactocerebroside, also both of which are sphingoglycolipid with accepted moisturizing effect.
  • An external composition for skin according to the second aspect of the invention contains an extract obtained from white bacteria of the genus Sphingomonas.
  • the white bacteria specified herein refer to those lacking color typically observed in previously-known strains of genus Sphingomonas, or to those appearing lighter even if they have color.
  • the white bacteria are not limited to those the look white by visual observation, but also include those with no color or pale color. Strains with no color are most preferable for the present invention. Such white bacteria have never been found in genus Sphingomonas, and are identified as novel strains.
  • the white bacteria can be referred as strains of genus Sphingomonas having no or little color substance. All of strains of genus Sphingomonas previously known exhibit yellowish color due to their production of carotenoid dyes. On the contrary, the white bacteria are new ones producing no or little carotenoid dyes.
  • strains of white bacteria are available in this invention as far as they belong to genus Sphingomonas.
  • strains of any one of classifications such as Sphingomonas paucimobilis, Sphingomonas capsulata, and Sphingomonas adhaesiva are acceptable.
  • Typical white bacteria include Sphingomonas paucimobilis KFC-W-1; deposition Nos. FERM P-16238 and BP-6368), Sphingomonas paucimobilis MK-253W; deposition Nos. FERM P-16693 and BP-6369), Sphingomonas paucimobilis MK-254W; deposition No. FERM P-16694 and BP-6370) and Sphingomonas paucimobilis MK-332W; deposition No. FERM P-16695 and BP-6371).
  • These white bacteria are roughly classified into two groups based on their properties.
  • One of these groups is characterized by exhibiting citric acid metabolizing property in Chrinstensen's citric acid agar medium, producing no hydrogen sulfide, and hydrolyzing Tween 20, where KFC-W-1 belongs thereto.
  • Another one is characterized by having no citric acid metabolizing property in Christensen's medium, producing hydrogen sulfide, showing no hydrolysis of Tween 20, where MK-253W, MK-254W and MK-332W belong thereto. Any other white strain which does not belong to the above groups can also be used in this invention.
  • Obtaining the white strain by mutation can start from a colored strain of genus Sphingomonas whose properties and types are not limited. It is, however, more preferable to start from colored strains which have greater proliferating potential, since in general such colored strains can yield mutants having larger proliferating potential.
  • the mutant can be obtained by any conventional method for obtaining mutants. It is such that culturing in a medium for a certain period, thoroughly replacing the culture liquor to prepare a new medium, again culturing in the new medium for a certain period, and repeating these steps afterwards.
  • the four above strains were successfully obtained by such method from the eleventh culture liquor containing strains of genus Sphingomonas (IAM 12576) at a probability of 1/10 9 cells.
  • a medium used for obtaining such mutant can be selected from a variety of those used generally in bacterial culture.
  • a preferable medium relates to that can help growth of a strain of genus Sphingomonas.
  • Exceptionally preferable one is a mixed medium containing compounds selected from of (1) glucose, (2) yeast extract, and (3) sodium glutamate, L-glutamic acid and glycine. This preferable medium will be described below.
  • Ratio of contents of individual components in the medium (1):(2):(3) is preferably set at 1:0.3-1.0:0.05-0.5,and more preferably at 1:0.4-0.7:0.1-0.3.
  • Sodium glutamate is a better choice as component (3).
  • Concentrations of the individual components contained in the medium is set in a concentration range by which strains of genus Sphingomonas will grow well.
  • a preferable concentration range for glucose is between 0.2 and 10 wt %, both ends inclusive.
  • a preferable concentration range for yeast extract is between 0.1 and 10 wt %, both ends inclusive.
  • a preferable concentration range for a compound selected from a group consisting of sodium glutamate, L-glutamic acid and glycine is between 0.05 and 10 wt %, both ends inclusive.
  • a good medium is typically expressed as containing 0.5 to 3 wt % of glucose, 0.1 to 1 wt % of yeast extract, and 0.05 to 0.5 wt % of a compound selected from a group consisting of sodium glutamate, L-glutamic acid and glycine.
  • a still more preferable medium is expressed as 0.7 to 1.5 wt % of glucose, 0.3 to 0.7 wt % of yeast extract, and 0.1 to 0.3 wt % of a compound selected from a group consisting of sodium glutamate, L-glutamic acid and glycine.
  • This medium can contain a small amount of basic inorganic components such as sodium, potassium, calcium, magnesium, phosphorus, and chlorine. A very small amount of other inorganic components, amino acid, vitamin and hormone are also permissible.
  • the medium can have any form of solid, semi-solid or liquid.
  • Agar, gelatin and silica gel are also allowable to prepare solid and semi-solid media.
  • a medium containing 1.0% glucose, 0.5% yeast extract and 0.2% glutamic acid can give a proliferation potential much greater than that is given by a medium containing 3.0% glucose, 0.1% ammonium chloride, 0.1% ammonium sulfate, 0.05% dipotassium hydrogen phosphate, 0.05% magnesium sulfate heptahydrate, 0.05% potassium chloride and 0.001% iron sulfate heptahydrate.
  • the above medium can also provide a much greater proliferation rate as compared with a case using a medium containing 1.0% glucose, 0.5% yeast extract and 0.2% cassamino acids.
  • the above medium is much advantageous in obtaining a large amount of sphingoglycolipid in a shorter period, since it allows very efficient growth of strains in genus Sphingomonas.
  • Culture conditions for obtaining the mutant can properly be determined.
  • the culture is generally run at around room temperature to 40° C., and for three hours to one week per run. It is recommended to shake the medium containing the strain using a shaker or so according to the general culture methods.
  • white bacteria of the invention it is possible to obtain a white composition containing sphingoglycolipid.
  • the term “white” defined in the invention also covers a compound with a more pale appearance as compared with that of sphingoglycolipid-containing composition derived in a similar manner from colored bacteria.
  • Such white sphingoglycolipid is directly applicable to cosmetic or other products which require aesthetic properties, without being subjected to a decoloring process.
  • white sphingoglycolipid contains no coloring component, or even if it does, at a very small and negligible amount, so that any decoloring process needed previously can be abandoned.
  • white sphingoglycolipid-containing composition is obtained at a good economic efficiency, which promises a large industrial merit.
  • a method for obtaining the white sphingoglycolipid-containing composition is not limited to a special one. Any usual extraction method is applicable to obtain the sphingoglycolipid-containing composition. Most preferable method relates to that provided according to the first aspect of the invention.
  • the sphingoglycolipid-containing composition isolated from the white bacteria has an excellent moisturizing effect and skin roughness protection effect, and is confirmed that it can give an appropriate moisture to skin surface to keep its smoothness. Such effects are confirmed to be equal to or higher than those of colored sphigoglycolipid-containing composition obtained from colored bacteria.
  • the external composition for skin according to the third aspect of the invention is comprises the structure represented by formula (1) shown in the above.
  • R 1 represents a sugar portion consisting of one to four hexoses selected from a group consisting of uronic acid, glucosamine, galactose and mannose, or a single uronic acid.
  • one to four hexoses one to four units are selected from uronic acid, glucosamine, galactose and mannose to be combined, where the number of each hexose, sequence, bond form and optical isomerism are not restricted.
  • Typical combinations of R 1 include that having uronic acid as an only hexose; that having one uronic acid, one glucosamine, one galactose and one mannose to be totaled as four hexoses; that having one uronic acid, one glucosamine and one galactose to be totaled as three hexoses; and that having one uronic acid, one galactose and two glucoses to be totaled as four hexoses.
  • R 1 is typically represented by structures A to D as shown in the above.
  • R 2 in formula (1) represents an alkyl group, an alkenyl group or an alkynyl group which may have a cycloalkyl group.
  • the alkyl, alkenyl and alkynyl groups representing R 2 are straight or branched, and both of those substituted with a hydroxyl group or so, and unsubstituted are allowable.
  • the alkyl group can include in its chain a cycloalkyl group such as a cyclopropyl group. There is also no limitation on the position of a double bond in the alkenyl group or a triple bond in the alkynyl group.
  • R 2 is typically represented by structures a to c as shown in the above.
  • R 3 represents an alkyl group.
  • R 3 is straight or branched, and both of those substituted with a hydroxyl group or so, and unsubstituted are allowable.
  • the alkyl group generally has 1 to 50 carbon atoms, preferably 15 to 25 carbon atoms.
  • R 3 is typically referred to a straight alkyl group having 12 carbon atoms.
  • a group of sphingoglycolipids favorably used for the external composition for skin of the invention can be represented by formula (1) where R 1 represents a sugar portion given by structures A, B, C or D; and R 3 represents a straight alkyl group having 12 carbon atoms.
  • R 2 is given by structures a, b or c; and R 3 represents a straight alkyl group having 12 carbon atoms.
  • a still more favorable group of sphingoglycolipids can be represented by formula (1) where R 1 represents a sugar portion given by structures A, B, C or D; R 2 is given by structures a, b or c; and R 3 represents a straight alkyl group having 12 carbon atoms.
  • sphingoglycolipids given by formula (1) can be included singly in an external composition for skin of the invention, or can be included in combination with two or more of them.
  • the ratio of contents of individual components there is no special limitation on the ratio of contents of individual components.
  • Sphingoglycolipids of formula (1) are obtained by extracting bacterial body containing sphingoglycolipid. Since sphingoglycolipid is contained in bacterial bodies which belong to the genus Sphingomonas, any bacterial body that belongs to the genus Sphingomonas can yield the sphingoglycolipid given by formula (1) through extraction.
  • the sphingoglycolipid given by formula (1) is insoluble in acetone, so that it is preferable to wash the bacterial body with acetone before extraction.
  • alcoholic solvent such as methanol
  • mixed solvent of polar solvents such as alcoholic solvent admixed with chloroform are preferable in terms of yield.
  • Other solvents will be also acceptable provided that they can solubilize the sphingoglycolipid.
  • a mixture of the sphingoglycolipid When a mixture of the sphingoglycolipid is obtained, individual components can be separated by a method known in this technical field. Chromatographic method, for example, can completely separate individual sphingoglycolipids having as R 1 structure A, structure B, structure C and structure D. When chloroform-methanol mixed solvent is used, individual sphingoglycolipids having structure A, structure D, Structure B and Structure C are eluted in this order, which facilitates the separation. Chromatographic conditions such as types of packed material, eluent, elution velocity, pressure and temperature are adjusted properly. It is also advantageous to prepare a derivative of a certain substance contained in the mixture of the sphingoglycolipid using a reagent that specifically reacts with that substance, and run the separation using chemical or physical properties of such derivative.
  • Use of Sphingomonas paucimobilis generally yields sphingoglycolipids of formula (1) having as R 1 structures A and B.
  • Use of Sphingomonas capsulata generally yields sphingoglycolipids of formula (1) having as R 1 structures A and C.
  • Use of Sphingomonas adhaesiva generally yields sphingoglycolipids of formula (1) having as R 1 structure A and D.
  • Sphingoglycolipid of formula (1) It is also possible to synthesize Sphingoglycolipid of formula (1) by combining synthetic methods which have previously been known. Individual sphingoglycolipids given by formula (1) can be prepared by, for example, previously synthesizing the sugar and sphingosine portions, and then forming an amide bond therebetween.
  • the morphology of the external composition for skin of the invention there is no limitation on the morphology of the external composition for skin of the invention.
  • any form of solid, liquid, paste, jelly or powder is acceptable. It is possible to accomplish such forms by, for example, solidification with an aid of gellation agent, dispersion using liquid, solubilization by adding solvent, or pulverization through spray drying.
  • the external compositions for skin of the invention have excellent moisturizing and skin roughness preventing effects and is confirmed that it can provide appropriate moisture to skin surface to retain its smoothness. That is, the external compositions for skin of the invention can retain the moisture of skin for an extended period. Such effects are much superior to those of gangliosides or galactocerebrosides, also both of which are sphingoglycolipids with accepted moisturizing effect. Thus the external composition for skin of the invention can prove its merits in applications where improvements in skin roughness and keratin conditions, or skin protection is required.
  • the external composition for skin of the invention also has anti-atopic activity, allowing it to be applied to prevention and therapy of atopic dermatitis.
  • the external composition for skin of the invention is available, for example, as a cosmetic or medicine. Possible applications include toilet soap, shampoo, cleansing foam, rinse, eye cream, eye shadow, cream or milky lotion, toilet lotion, perfume, face powder, facial oil, hair-care cosmetics, hair dye, jelly fragrance, powder, pack, shaving cream, shaving lotion, suntan oil, anti-suntan oil, suntan lotion, sun-screening lotion, suntan cream, sun-screening cream, foundation, powdery fragrance, cheek rouge, mascara, eyebrow pencil, nail cream, nail enamel, nail enamel remover, hair cleaner, bath cosmetics, lipstick, lip cream, eyeliner, toothpaste, deodorant agent, eau de cologne, hair tonic, or hair restorer.
  • the external composition for skin of the invention can also successfully be used as an ointment or wet pack.
  • the external composition for skin of the invention can contain various components besides sphingoglycolipids according to purposes of its use.
  • Appropriate components can be added to enhance emollient property, to improve feeling, to reduce dryness after use, to improve solubility, to improve emulsifying property, to improve emulsion stability, to improve compatibility with oily components, to reduce stretched sense after use, to improve adhering to skin, to improve spreadability on skin, to reduce stickiness, to prevent skin roughness, to enhance skin refining effect, to enhance skin protection effect, to improve horny layer, to normalize epidermal keratinization (prevention of partial keratinization due to turnover acceleration, prevention of epidermal thickening, suppression of disorder in epidermal lipid metabolism), to moderate xeroderma such as senile xeroderma, to improve dried skin conditions such as chapping and scaling, to suppress wrinkles formation, to remove wrinkle, to heal wounds, to prevent and improve pigmentation, to delay aging, to reduce d
  • Possible additives for the external compositions for skin of the invention include, for example, oil and fat components, phospholipid, UV absorber, infrared absorber, emulsifier, surfactant, aseptic agent, mildewproof agent, antioxidant, whitening agent, vitamin, amino acid, hormone, peptide, bioactive plant extract, fluorescent material, pigment, dye, perfumery, scrub material, metal ion blocker, binder, filler, thickener, saccharide, nutrient, pH adjuster, chelating agent, sterilizer, keratin conditioner, keratin solubilizer, antibiotic, dermal permeation accelerator, circulation accelerator, antiphlogistic, cell activator, anti-inflammatory, anodyne, emollient agent, skin relaxing agent, traumatic remedy, metabolic accelerator, all of which are compoundable depending on purposes. It is also allowable to add moisturizing components other than active components of the invention.
  • Oil and fat components compoundable with the external composition for skin of the invention include fatty acids (e.g. oleic acid, behenic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, linoleic acid, ⁇ -linolenic acid, cholumbinic acid, eicosa-(n-6,9,13)-trienic acid, arachidonic acid, ⁇ -linolenic acid, Tymnodonic acid, and hexaenic acid), ester oils (e.g.
  • waxes e.g. beeswax, whale wax, lanoline, carnauba wax, candelilla wax and vaseline
  • animal and plant oils e.g. mink oil, olive oil, castor oil, cocoa butter, palm oil, cod-liver oil, beef tallow, butter, evening primrose oil rice bran oil and squalane
  • mineral oils e.g.
  • hydrocarbon oils and liquid paraffin silicone oils (e.g. metylphenyl silicone and dimethyl silicone), higher alcohols (e.g. lauryl alcohol, stearyl alcohol, oleyl alcohol, cetyl alcohol, 2-octyl dodecanol and 2-decyltetradecanol) and their derivatives.
  • Allowable organic acids include ⁇ -hydroxylic acid, hydroxycarboxylic acid, dicarboxylic acid, glycyrrhizic acid, glycyrrhetinic acid and mevalonic acid (mevalonolactone).
  • Phospholipids compoundable with the external composition for skin of the invention include glycerophospholipids of the monoacyl ester type or diacyl ester type. They are enumerated as lysophosphatidyl choline, lysophosphatidyl ethanolamine, lysophosphatidyl serine, lysophosphatidyl inositol, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine, phosphatidyl glycerol, phosphatidic acid and sphingomyelin. Natural source lecithin (e.g. yolk) and hydrogenated compounds of the substances listed above are also available.
  • Natural source lecithin e.g. yolk
  • hydrogenated compounds of the substances listed above are also available.
  • UV absorbers compoundable with the external compositions for skin of the invention typically include oxybenzone (2-hydroxy-4-methoxybenzophenone), oxybenzonesulfonic acid, oxybenzone-sulfonic acid (trihydrate), guaiazulene, ethylene glycol salicylate, octyl salicylate, dipropylene glycol salicylate, phenyl salicylate, homomentyl salicylate, methyl salicylate, methyl diisopropyl cinnamate, cinoxate (p-methoxycinnamic acid 2-ethoxyethyl ester), di-p-methoxycinnamic acid mono-2-ethyl-hexylacid glyceryl, dihydroxymethoxybenzophenone, dihydroxy-methoxybenzophenone sodium disulfonate, dihydroxybenzophenone, tetrahydroxy-benzophenone, p-aminobenzoic acid, ethyl p-a
  • Emulsifiers and surfactants compoundable with the external compositions for skin of the invention include nonionic surfactants, anionic surfactants and cationic surfactants.
  • nonionic surfactants enumerated are sorbitan ester (e.g. sorbitan monolaurate, sorbitan monooleate, sorbitan monoisostearate), polyoxyethylene sorbitan ester (e.g. polyoxyethylene sorbitan monoisostearate, polyoxyethylene sobitan monolaurate, polyoxyethylene sorbitan monooleate), glycerol esters (e.g. glycerol monoisostearate, glycerol monomyristate), polyoxyethylene glycerol ether (e.g.
  • polyoxyethylene glycerol monoisostearate polyoxyethylene glycerol monomyristate
  • polyglycerin fatty acid ester e.g. diglyceryl monostearate, decaglyceryl decaisostearate, diglyceryl diisostearate
  • glycerin fatty acid esters e.g.
  • glyceryl monocaprate glyceryl monolaurate, glyceryl monomyristate, glyceryl monopalmitate, glyceryl monooleate, glyceryl monostearate, glyceryl monolinoleate, glyceryl monoisostearate, glyceryl monodilinoleate, glyceryl monodicaprate
  • polyoxyethyleneglycerin fatty acid esters e.g. polyoxyethyleneglyceryl monomyristate, polyoxyethyleneglyceryl monooleate, polyoxyethyleneglyceryl monostearate
  • polyoxyethylene branched alkyl ethers e.g.
  • polyoxyethylene octyl dodecyl alcohol polyoxyethylene-2-decyl tetradecyl alcohol
  • polyoxyethylene alkyl ether e.g. polyoxyethylene oleyl alcohol ether, polyoxyethylene cetyl alcohol ether
  • polyoxyethylene hydrogenated castor oil fatty acid ester e.g. polyoxyethylene hydrogenated castor oil, polyoxyethylene dihydrocholesterol ether, polyoxyethylene hydrogenated castor oil isostearate
  • polyoxyethylene alkyl aryl ether e.g. polyoxyethylene octylphenol ether
  • the anionic surfactants are enumerated as salts (e.g. diethanolamine salt, triethanolamine salt, amino acid salt, potassium salt, sodium salt) of higher fatty acids (e.g. oleic acid, stearic acid, isostearic acid, palmitic acid, myristic acid, behenic acid), ethercarboxylic acid alkaline salts, N-acylamino acid salts, N-acylsalcone salts, and higher alkyl sulfonic acid salts.
  • higher fatty acids e.g. oleic acid, stearic acid, isostearic acid, palmitic acid, myristic acid, behenic acid
  • ethercarboxylic acid alkaline salts e.g. oleic acid, stearic acid, isostearic acid, palmitic acid, myristic acid, behenic acid
  • ethercarboxylic acid alkaline salts e.g. oleic acid,
  • Typical cationic surfactants and ampholytic surfactants are alkyl quaternary ammonium salts, polyamine, and alkylamine salts.
  • Powdery agents compoundable with the external compositions for skin of the invention include talc, kaolin, fuller's earth, rubber, starch, silica, silicic acid, aluminum slicate hydrate, chemically modified aluminum magnesium silicate, sodium polyacrylate, tetraalkylaryl snuctite, trialkylarylammonium snuctite, ethylene glycol monostearate, sodium carboxymethylcellulose, carboxyvinyl polymer, chalk, gum, ethylene glycol monostearate, and ethylene glycol distearate.
  • Polyols compoundable with the external compositions for skin of the invention include polyglycerins such as glycerin, diglycerin, triglycerin or tetraglycerin; ethylene glycol, propylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, dipropylene glycol, polyethylene glycol, sorbitol, erythritol, maltotriose, threitol, sucrose, glucose, maltose, multitose, fructose and xylitose.
  • polyglycerins such as glycerin, diglycerin, triglycerin or tetraglycerin
  • ethylene glycol propylene glycol
  • 1,3-butylene glycol 1,4-butylene glycol
  • dipropylene glycol polyethylene glycol
  • sorbitol erythritol
  • maltotriose threitol
  • sucrose
  • vitamins e.g. vitamin A, vitamin B 1 , vitamin B 2 , vitamin B 6 , vitamin B 12 , vitamin C, vitamin D, vitamin E, vitamin K
  • amino acids e.g. proline, leucine, isoleucine, alanine, threonine, lysine, cysteine, arginine
  • hormones e.g. estrogen, pregnenolone, adrenal cortex hormone
  • peptides e.g. keratin, collagen, elastin
  • saccharides e.g.
  • sphingosine dihydrosphingosine, phytosphingosine, dehydrosphingosine, dehydrophytosphingosine, sphingadienine), ceramide, pseudoceramide, saponin, chitin derivatives, oligosaccharides (e.g.
  • maltose xylobiose, isomantose, lactose, sucrose, raffinose, maltotriose, xylotriose, maltotetraose, xylotetraose, maltopentaose, xylopentaose, maltohexaose, xylohexaose, maltoheptaose, xyloheptaose), acidic mucopolysaccharides (hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparin, heparan sulfate), and yeast extract.
  • Still other materials compoundable with the external composition for skin of the invention include thickeners (e.g. carboxyvinyl polymer, carboxymethylcellulose, polyvinyl alcohol, carrageenan, alginate, arginic acid propylene glycol ester, gelatin, electrolytes such as sodium chloride), whitening agent (e.g.
  • stearyl alcohol glyceryl monoricinoleate, mink oil, cetyl alcohol, stearic acid, palm oil, castor oil, oxostearic acid
  • skin relaxing agents e.g. stearyl alcohol, glycerin monoricinoleate, glycerin monostearate, cetyl alcohol
  • skin permeation accelerator e.g. 2-methylpropane-2-ol, 2-propanol, ethyl-2-hydroxypropanoate, 2,5-hexanediol, acetone, tetrahydrofuran
  • biologically active plant extracts e.g.
  • extracts from aloe, arnica, licorice, sage or swertia herb preservatives (e.g. p-hydroxybenzoate, sodium benzoate, urea, metylparaben, ethylparaben, propylparaben, butylparaben), agents (e.g. ⁇ -tocopherol, butylhydroxytoluene), buffers (e.g. combination of lactic acid with triethanolamine or sodium hydroxide), keratin solubilizers (e.g. lactic acid, glycolic acid, malic acid, tartaric acid, citric acid), scrubbing materials (e.g. polyethylene powder), and pigments (e.g. lake of calcium, barium or aluminum, iron oxide, titanium dioxide, mica).
  • preservatives e.g. p-hydroxybenzoate, sodium benzoate, urea, metylparaben, ethylparaben, propylparaben, buty
  • the external compositions for skin of the invention are widely used in the field where moisturizing and anti-atopic effects are required.
  • the amount of use will be determined so that the desired moisturizing effect is fully achieved.
  • a medium containing 1.0% glucose, 0.5% yeast extract and 0.2% sodium glutamate (adjusted to pH 7.0 with citric acid) was put into a 500-ml conical flask, and a strain of genus Sphingomonas (IAM 12576) was then added.
  • the content was cultured under shaking using a shaker at 30° C. for 20 hours.
  • the medium was thoroughly removed and another 50 ml of medium with the above composition was newly added, which was again cultured under shaking using a shaker at 30° C. for 20 hours.
  • the obtained culture liquor was diluted and sprayed on a plate medium with the above composition. From this culture liquor, Sphingomonas paucimobilis KFC-W-1 (Deposition Nos. FERM P-16238 and BP-6368) was found and collected (at a frequency of 1/10 9 cells).
  • Sodium glutamate in medium 1 was then replaced with L-ornithine hydrochloride, glycine, L-leucine, L-methionine, L(+)-lysine hydrochloride, L-cyctein hydrochloride hydrate, L-glutamic acid, L-tryptophan and DL-phenylalanine, respectively, and again similar experiments were performed. It was observed that glycine and L-glutamic acid can cause a proliferation at a level comparable to that for sodium glutamate.
  • Example 1 The white bacteria obtained as decribed in Example 1 were cultured at room temperature for 24 hours. The culture was run using a medium containing 1.0% glucose, 0.5% yeast extract and 0.2% sodium glutamate (adjusted to pH7.0 with citric acid) under aeration at 0.7 vvm.
  • the bacterial bodies were collected by centrifugation. Twenty kg of the bacterial bodies were then added to 30 liters of acetone, stirred, and collected by filtration. Thus obtained bacterial bodies were extracted three times with 30 liters each of acetone, and resultant extracts were distilled using a flash evaporator to remove the solvent. Four liters of residual liquor is added with 8 liters of acetone, stirred, and allowed to stand for precipitation. The precipitate was collected, added with another 2 liters of acetone, and again allowed to stand to produce the precipitate. The precipitate was finally collected, dewatered, and dried under reduced pressure to prepare the white composition comprising sphingoglycolipid.
  • Sphingomonas paucimobilis (IAM12576) was cultured at room temperature for 24 hours. The culture was run using a medium containing 1.0% glucose, 0.5% yeast extract and 0.2% sodium glutamate (adjusted to pH7.0 with citric acid) under aeration at 0.7 vvm.
  • the bacterial bodies were collected by centrifugation. Twenty kg of the fungus body was then added with 30 liters of acetone, stirred, and collected by filtration. Thus obtained bacterial bodies were extracted three times with 30 liters each of solvent shown in Table 4, and the resultant extracts were distilled using a flash evaporator to remove the solvent. Four liters of residual liquor is added with 8 liters of acetone, stirred, and allowed to stand for precipitation. The precipitate was collected, added with another 2 liters of acetone, and again allowed to stand to produce the precipitate. The precipitate was finally collected, dewatered, and dried under reduced pressure to prepare the composition comprising sphingoglycolipid (Samples 1 to 19).
  • sphingoglycolipid-containing compositions prepared in Examples 3 and 4 and at least one active component selected from a group listed below (represented by formula (1) where R 3 for all the components is a straight alkyl group having 12 carbon atoms).
  • a first liquid prepared by mixing individual components listed below at 75° C. was added to a second liquid prepared by mixing individual components listed below at 75° C., and then thoroughly emilsified at 75° C. to produce a toilets milky lotion.
  • 1,3-butylene glycol and purified water were first mixed and heated to 70° C., to which a molten mixture of the residual components was added, which was followed by homogenizing the emulsified particles using a homomixer and cooled to produce a emollient cream.
  • Active component 1.0 Zinc sulfophenolate 1.0 Isopropylmyristic acid ester 7.0 Isopropylpalmitic acid ester 8.0 Ethanol 82.5 Perfume 0.5
  • palmitic acid, myristic acid, lauric acid, palm oil and aseptic agent were melted by heating and kept at 70° C., to which a mixture of potassium hydroxide and purified water was added, which was followed by adding the residual components and thorough stirring, to produce a cleansing foam.
  • titanium oxide and talc were thoroughly dispersed in purified water, to which sorbitol was added and heated to 70° C. to be dissolved, then the residual components were added and thoroughly stirred, which was followed by degassing and cooling to produce a pasty pack.
  • active component active component
  • stearic acid stearyl alcohol
  • butyl stearate each of which was previously heated to 70° C.
  • Example 7 Components weight part Composition of Example 7 3.0 Vaseline 24.0 Stearyl alcohol 21.0 Propylene glycol 13.0 Polyoxyethylene hardened castor oil 3.5 Glycerin monostearate 1.0 Aseptic agent 0.2 Purified water 34.3

Abstract

The present application discloses an external composition for skin comprising a component obtaind by washing a bacterium of the genus Sphingomonas with acetone and then extracting the resultant with alcohol or alcohol-water mixture; an external composition for skin comprising a component extracted from a white bacterium of the genus Sphingomonas; and an external composition for skin comprising a sphingoglycolipid represented by the following formula:
Figure US06348201-20020219-C00001
where, R1 represents a sugar portion consisting of a single uronic acid or one to four hexoses selected from a group consisting of uronic acid, glucosamine, galactose and mannose; R2 represents an alkyl group which may have a cycloalkyl group, an alkenyl group or an alkynyl group; and R3 represents an alkyl group; these alkyl, alkenyl and alkynyl groups being straight or branched, and substituted or unsubstituted. These external compositions for skin exhibit excellent moisturizing and skin roughnes prevention effects.

Description

BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to external compositions for skin comprising sphingoglycolipid available as cosmetic and medicine. The external compositions for skin of the present invention have a potent moisturizing effect and preventive effect against skin roughness.
2. Description of the Related Arts
Skin roughness is caused by losing moisture from the skin surface during dry weather or cleansing. Miscellaneous chemical substances present in modern society can contact skin to inhibit skin functions, which may also result in skin roughness due to depression of lipid secretion ability. It is thus expected to provide external compositions for skin having an excellent moisturizing effect and capable of preventing skin roughness before it occurs.
Various compounds have been proposed as active moisturizers, typified by water-soluble polyol, some of which have already been put into practical use. Many of such moisturizing compounds already put into practical use, however, suffer from uncomfortability upon application or from insufficient moisturizing effect. Thus a new moisturizing compound is still awaited.
In such situation, sphingoglycolipid has been attracting an attention as a safe moisturizing compound.
For example, JP-A-H1-242690, H2-48520, H4-159203 and JP-B-H6-80007 describe that sphingoglycolipid has a skin moisturizing effect. Structures and compositions of the sphingoglycolipids appears in these patent specifications are, however, not clearly disclosed.
JP-A-H6-157283 describes a moisturizing external cutaneous cosmetic containing, as its one component, a sphingoglycolipid represented by a specific general formula. The sugar portion of this general formula is, however, expressed simply as a saccharide residue without mentioning its details.
JP-A-S61-286307 clearly specifies a sphingoglycolipid having a moisturizing effect. This patent describes that ganglioside has skin moisturizing and emollient effects and discloses skin cosmetics containing such ganglioside or its salts. Ganglioside refers to a sphingoglycolipid typically containing neutral sugar, amino sugar and sialic acid.
JP-A-H5-39485, H7-133217 and H7-285827 disclose an external cutaneous remedy using cerebroside. Cerebroside refers to a sphingoglycolipid containing 1 mol each of fatty acid, sphingosine base and neutral sugar (galactose or glucose).
Although several sphingoglycolipids as mentioned above have been known, their moisturizing effects are not always enough to be satisfactory. Cosmetics applied to the skin are also required to exert a preventive effect against skin roughness, as well as a moisturizing effect. But previously-known sphingoglycolipid cannot satisfy the expected preventive effect against skin roughness.
It is thus an object of the present invention to provide an external composition for skin comprising Sphingomonas strain extract having an excellent moisturizing effect and preventive effect against skin roughness. It is another object of the present invention to provide an external composition for skin comprising an extract with a color lighter than that of the previous extracts from Sphingomonas strains. It is another object of the present invention to provide Sphingomonas strains capable of producing such extract with a lighter color. It is still another object of the present invention to identify structures of sphingoglycolipids having potent moisturizing and skin roughness preventive effects and to provide an external composition for skin comprising such glycolipids.
These and other objects will be apparent from the description in the entire part of this specification.
DISCLOSURE OF THE INVENTION
After a series of thorough investigations, the present inventors succeeded in obtaining extracts having potent moisturizing and skin roughness preventive effects by extracting Sphingomonas strain according to a specially designed method, and accomplished the present invention. Thus the first aspect of the invention relates to providing an external composition for skin obtained by washing Sphingomonas strain with acetone, and extracting the resultants with alcohol or alcohol-water mixture. Preferable extracting solutions are methanol, propanol-water mixture or butanol-water mixture. Propanol content in propanol-water mixture is preferably 75 wt % or below. Butanol content in butanol-water mixture is preferably 95 wt % or below, and more preferably 85 to 95 wt %, both ends inclusive.
The second aspect of the invention relates to provide an external composition for skin comprising an extract obtained from white bacteria of the genus Sphingomonas, in particular from Sphingomonas paucimobilis. Preferable white bacteria include Sphingomonas paucimobilis KFC-W-1; deposition Nos. FERM P-16238 and BP-6368), Sphingomonas paucimobilis MK-253W; deposition Nos. FERM P-16693 and BP-6369), Sphingomonas paucimobilis MK-254W; deposition No. FERM P-16694 and BP-6370) and Sphingomonas paucimobilis MK-332W; deposition No. FERM P-16695 and BP-6371).
The third aspect of the invention relates to an external composition for skin comprising a sphingoglycolipid represented by a formula shown below:
Figure US06348201-20020219-C00002
In the above formula, R1 represents a sugar portion consisting of a single uronic acid or one to four hexoses selected from a group consisting of uronic acid, glucosamine, galactose and mannose; R2 represents an alkyl group which may have a cycloalkyl group, an alkenyl group or an alkynyl group; and R3 represents an alkyl group; these alkyl, alkenyl and alkynyl groups being straight or branched, and substituted or unsubstituted.
R1 preferably consists of three to four hexoses. More preferably, R1 is any one of a four-hexose sugar portion consisting of uronic acid, glucosamine, galactose and mannose; a three-hexose sugar portion consisting of uronic acid, glucosamine, and galactose; or a two-hexose sugar portion consisting of uronic acid and galactose. Still more preferably, R1 is represented by any one of the following formulae:
Figure US06348201-20020219-C00003
R2 preferably has 15 to 25 carbon atoms, and more preferably has any one of the following structures:
Figure US06348201-20020219-C00004
R3 is preferably a substituted or unsubstituted straight alkyl group having 10 to 20 carbon atoms, and more preferably a straight alkyl group having 10 carbon atoms.
The external composition for skin of the invention is available as for example toilet soap, shampoo, cleansing foam, rinse, eye cream, eye shadow, cream or milky lotion, toilet lotion, perfume, face powder, facial oil, hair-care cosmetics, hair dye, jelly fragrance, powder, pack, shaving cream, shaving lotion, suntan oil, anti-suntan oil, suntan lotion, sun-screening lotion, suntan cream, sun-screening cream, foundation, powdery fragrance, cheek rouge, mascara, eyebrow pencil, nail cream, nail enamel, nail enamel remover, hair cleaner, bath cosmetics, lipstick, lip cream, eyeliner, toothpaste, deodorant agent, eau de cologne, hair tonic, hair restorer, ointment, wet pack, medicated lip cream or anti-atopic agent. The external composition for skin of the invention can contain at least one additive selected from a group consisting of whitening agent, surfactant, dye, perfumery, aseptic agent, pigment, mildewproof agent, antioxidant, UV absorber, infrared absorber, fluorescent material, metal ion blocker, binder, filler, antiphlogistic, circulation accelerator, cell activator and antibiotic.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
An external composition for skin according to the first aspect of the invention comprises an extract obtained by washing Sphingomonas strain with acetone and successive extraction with alcohol or alcohol-water mixture.
Strains applicable to the present invention belong to the genus Sphingomonas. Strains in the genus Sphingomonas are known for their ability to produce various components including sphingoglycolipid. Any strain is allowable for the present invention provided that it belongs to genus Sphingomonas. Thus any strain in the classifications of Sphingomonas paucimobilis, Sphingomonas capsulata, or Sphingomonas adhaesiva is available.
Although they are typically listed as Sphingomonas paucimobilis FERM BP-3631, Sphingomonas paucimobilis FERM BP-3632, Sphingomonas paucimobilis FERM BP-3633, Sphingomonas paucimobilis FERM BP-3634, Sphingomonas capsulate FERM BP-3709 and Sphingomonas adhaesiva FERM BP-3710, many other strains in the genus Sphingomonas are used in a similar manner.
The strain can be used either singly or in combination with other strain. Combination and mixing ratio of a plurality of strains is not limited.
To obtain an extracted component, the strain of genus Sphingomonas is first treated with acetone to thoroughly dewater the bacterial body, then the bacterial body is separated by a method, such as filtration. Acetone is most preferably used as a single solvent, but its mixtures with water-base solvent are also allowable. Addition volume of acetone is set between 0.1 to 1000 liters per 1 kg of wet fungus body, and more preferably between 1 to 10 liters.
After the addition of acetone, the contents of the bacterial body is thoroughly brought into contact with acetone. It is also recommendable to apply physical force to the bacterial body to raise the contact efficiency. There is no limitation on a contact duration as far as water in the bacterial body is successfully removed. Generally the duration is set to 20 seconds to 2 hours according to extent of the physical stress. After that the bacterial body is separated from the acetone solution by, for example, filtration.
Separated bacterial body is then extracted with alcohol or alcohol-water mixture. Alcohol used here is selected from hydrocarbon compounds having a hydroxyl group, and preferably from alkanol having 1 to 8 carbon atoms. For use of a single alcohol, preferable ones include methanol, propanol and butanol, where methanol excels the others. Structural isomers of propanol and butanol are also available, where n-propanol, isopropanol, and n-butanol are recommended.
As for use of alcohol-water mixture, propanol-water mixture and butanol-water mixture are preferable. Propanol content in propanol-water mixture is preferably set not higher than 90%, and more preferably not higher than 75%. Butanol content in butanol-water mixture is preferably set not higher than 95%, and more preferably between 80 to 95%.
Extraction using these solvents can comply with a method common in this technical field. For example, extraction is carried out once or repeated several times using approx. 1 to 50 liters of solvent per 1 kg of wet bacterial body.
Obtained extract is then distilled by a known method to remove the solvent to yield a residual syrup. Drying this residual syrup will result in a solid composition. It is also possible to obtain the solid composition by adding acetone to the residual syrup and by collecting the resultant precipitate by filtration or other methods.
Thus-obtained sphingoglycolipid composition possesses excellent moisturizing and skin roughness preventing effects and is confirmed that it can provide appropriate moisture to skin surface to retain its smoothness. Such effects are much more superior to those of ganglioside or galactocerebroside, also both of which are sphingoglycolipid with accepted moisturizing effect.
An external composition for skin according to the second aspect of the invention contains an extract obtained from white bacteria of the genus Sphingomonas.
The white bacteria specified herein refer to those lacking color typically observed in previously-known strains of genus Sphingomonas, or to those appearing lighter even if they have color. The white bacteria are not limited to those the look white by visual observation, but also include those with no color or pale color. Strains with no color are most preferable for the present invention. Such white bacteria have never been found in genus Sphingomonas, and are identified as novel strains.
From another viewpoint, the white bacteria can be referred as strains of genus Sphingomonas having no or little color substance. All of strains of genus Sphingomonas previously known exhibit yellowish color due to their production of carotenoid dyes. On the contrary, the white bacteria are new ones producing no or little carotenoid dyes.
Any strains of white bacteria are available in this invention as far as they belong to genus Sphingomonas. Thus strains of any one of classifications such as Sphingomonas paucimobilis, Sphingomonas capsulata, and Sphingomonas adhaesiva are acceptable.
Typical white bacteria include Sphingomonas paucimobilis KFC-W-1; deposition Nos. FERM P-16238 and BP-6368), Sphingomonas paucimobilis MK-253W; deposition Nos. FERM P-16693 and BP-6369), Sphingomonas paucimobilis MK-254W; deposition No. FERM P-16694 and BP-6370) and Sphingomonas paucimobilis MK-332W; deposition No. FERM P-16695 and BP-6371).
These white bacteria are roughly classified into two groups based on their properties. One of these groups is characterized by exhibiting citric acid metabolizing property in Chrinstensen's citric acid agar medium, producing no hydrogen sulfide, and hydrolyzing Tween 20, where KFC-W-1 belongs thereto. Another one is characterized by having no citric acid metabolizing property in Christensen's medium, producing hydrogen sulfide, showing no hydrolysis of Tween 20, where MK-253W, MK-254W and MK-332W belong thereto. Any other white strain which does not belong to the above groups can also be used in this invention.
There is no limitation on a method for obtaining the white strain. Those isolated from plants and soil, or those obtained after mutating conventional strains are both permissible. Obtaining the white strain by mutation can start from a colored strain of genus Sphingomonas whose properties and types are not limited. It is, however, more preferable to start from colored strains which have greater proliferating potential, since in general such colored strains can yield mutants having larger proliferating potential.
The mutant can be obtained by any conventional method for obtaining mutants. It is such that culturing in a medium for a certain period, thoroughly replacing the culture liquor to prepare a new medium, again culturing in the new medium for a certain period, and repeating these steps afterwards. The four above strains were successfully obtained by such method from the eleventh culture liquor containing strains of genus Sphingomonas (IAM 12576) at a probability of 1/109 cells.
A medium used for obtaining such mutant can be selected from a variety of those used generally in bacterial culture. A preferable medium relates to that can help growth of a strain of genus Sphingomonas. Exceptionally preferable one is a mixed medium containing compounds selected from of (1) glucose, (2) yeast extract, and (3) sodium glutamate, L-glutamic acid and glycine. This preferable medium will be described below.
Ratio of contents of individual components in the medium (1):(2):(3) is preferably set at 1:0.3-1.0:0.05-0.5,and more preferably at 1:0.4-0.7:0.1-0.3. Sodium glutamate is a better choice as component (3).
Concentrations of the individual components contained in the medium is set in a concentration range by which strains of genus Sphingomonas will grow well. A preferable concentration range for glucose is between 0.2 and 10 wt %, both ends inclusive. A preferable concentration range for yeast extract is between 0.1 and 10 wt %, both ends inclusive. And a preferable concentration range for a compound selected from a group consisting of sodium glutamate, L-glutamic acid and glycine is between 0.05 and 10 wt %, both ends inclusive.
A good medium is typically expressed as containing 0.5 to 3 wt % of glucose, 0.1 to 1 wt % of yeast extract, and 0.05 to 0.5 wt % of a compound selected from a group consisting of sodium glutamate, L-glutamic acid and glycine. A still more preferable medium is expressed as 0.7 to 1.5 wt % of glucose, 0.3 to 0.7 wt % of yeast extract, and 0.1 to 0.3 wt % of a compound selected from a group consisting of sodium glutamate, L-glutamic acid and glycine.
This medium can contain a small amount of basic inorganic components such as sodium, potassium, calcium, magnesium, phosphorus, and chlorine. A very small amount of other inorganic components, amino acid, vitamin and hormone are also permissible.
There is no special limitation on a carrier of the medium, so that the medium can have any form of solid, semi-solid or liquid. Agar, gelatin and silica gel are also allowable to prepare solid and semi-solid media.
Culture in these media will result in highly efficient proliferation of strains in genus Sphingomonas. The proliferation is much more remarkable than in a case using other media. That is, the strain can proliferate to a greater extent in a shorter time period than in media which have conventionally been used for proliferating or growing strains of genus Sphingomonas. For instance, a medium containing 1.0% glucose, 0.5% yeast extract and 0.2% glutamic acid can give a proliferation potential much greater than that is given by a medium containing 3.0% glucose, 0.1% ammonium chloride, 0.1% ammonium sulfate, 0.05% dipotassium hydrogen phosphate, 0.05% magnesium sulfate heptahydrate, 0.05% potassium chloride and 0.001% iron sulfate heptahydrate. The above medium can also provide a much greater proliferation rate as compared with a case using a medium containing 1.0% glucose, 0.5% yeast extract and 0.2% cassamino acids. Thus the above medium is much advantageous in obtaining a large amount of sphingoglycolipid in a shorter period, since it allows very efficient growth of strains in genus Sphingomonas.
Culture conditions for obtaining the mutant can properly be determined. The culture is generally run at around room temperature to 40° C., and for three hours to one week per run. It is recommended to shake the medium containing the strain using a shaker or so according to the general culture methods.
Using the white bacteria of the invention, it is possible to obtain a white composition containing sphingoglycolipid. The term “white” defined in the invention also covers a compound with a more pale appearance as compared with that of sphingoglycolipid-containing composition derived in a similar manner from colored bacteria. Such white sphingoglycolipid is directly applicable to cosmetic or other products which require aesthetic properties, without being subjected to a decoloring process. In other words, such white sphingoglycolipid contains no coloring component, or even if it does, at a very small and negligible amount, so that any decoloring process needed previously can be abandoned. Thus by using the white bacteria of the invention, white sphingoglycolipid-containing composition is obtained at a good economic efficiency, which promises a large industrial merit.
A method for obtaining the white sphingoglycolipid-containing composition is not limited to a special one. Any usual extraction method is applicable to obtain the sphingoglycolipid-containing composition. Most preferable method relates to that provided according to the first aspect of the invention.
The sphingoglycolipid-containing composition isolated from the white bacteria has an excellent moisturizing effect and skin roughness protection effect, and is confirmed that it can give an appropriate moisture to skin surface to keep its smoothness. Such effects are confirmed to be equal to or higher than those of colored sphigoglycolipid-containing composition obtained from colored bacteria.
The external composition for skin according to the third aspect of the invention is comprises the structure represented by formula (1) shown in the above.
In formula (1), R1 represents a sugar portion consisting of one to four hexoses selected from a group consisting of uronic acid, glucosamine, galactose and mannose, or a single uronic acid. As for one to four hexoses, one to four units are selected from uronic acid, glucosamine, galactose and mannose to be combined, where the number of each hexose, sequence, bond form and optical isomerism are not restricted. Typical combinations of R1 include that having uronic acid as an only hexose; that having one uronic acid, one glucosamine, one galactose and one mannose to be totaled as four hexoses; that having one uronic acid, one glucosamine and one galactose to be totaled as three hexoses; and that having one uronic acid, one galactose and two glucoses to be totaled as four hexoses.
R1 is typically represented by structures A to D as shown in the above.
R2 in formula (1) represents an alkyl group, an alkenyl group or an alkynyl group which may have a cycloalkyl group. Although the number of carbon atoms in R2 is not particularly limited, preferred number resides in a range from 15 to 25, both ends inclusive. The alkyl, alkenyl and alkynyl groups representing R2 are straight or branched, and both of those substituted with a hydroxyl group or so, and unsubstituted are allowable. The alkyl group can include in its chain a cycloalkyl group such as a cyclopropyl group. There is also no limitation on the position of a double bond in the alkenyl group or a triple bond in the alkynyl group.
R2 is typically represented by structures a to c as shown in the above.
R3 represents an alkyl group. R3 is straight or branched, and both of those substituted with a hydroxyl group or so, and unsubstituted are allowable. The alkyl group generally has 1 to 50 carbon atoms, preferably 15 to 25 carbon atoms. R3 is typically referred to a straight alkyl group having 12 carbon atoms.
A group of sphingoglycolipids favorably used for the external composition for skin of the invention can be represented by formula (1) where R1 represents a sugar portion given by structures A, B, C or D; and R3 represents a straight alkyl group having 12 carbon atoms.
Another favorable group of sphingoglycolipids can be represented by formula (1) where R2 is given by structures a, b or c; and R3 represents a straight alkyl group having 12 carbon atoms.
A still more favorable group of sphingoglycolipids can be represented by formula (1) where R1 represents a sugar portion given by structures A, B, C or D; R2 is given by structures a, b or c; and R3 represents a straight alkyl group having 12 carbon atoms.
These sphingoglycolipids given by formula (1) can be included singly in an external composition for skin of the invention, or can be included in combination with two or more of them. For the case with the combination, there is no special limitation on the ratio of contents of individual components.
Sphingoglycolipids of formula (1) are obtained by extracting bacterial body containing sphingoglycolipid. Since sphingoglycolipid is contained in bacterial bodies which belong to the genus Sphingomonas, any bacterial body that belongs to the genus Sphingomonas can yield the sphingoglycolipid given by formula (1) through extraction. The sphingoglycolipid given by formula (1) is insoluble in acetone, so that it is preferable to wash the bacterial body with acetone before extraction. As a solvent used for extracting sphingoglycolipid of formula (1), alcoholic solvent such as methanol, or mixed solvent of polar solvents such as alcoholic solvent admixed with chloroform are preferable in terms of yield. Other solvents will be also acceptable provided that they can solubilize the sphingoglycolipid.
When a mixture of the sphingoglycolipid is obtained, individual components can be separated by a method known in this technical field. Chromatographic method, for example, can completely separate individual sphingoglycolipids having as R1 structure A, structure B, structure C and structure D. When chloroform-methanol mixed solvent is used, individual sphingoglycolipids having structure A, structure D, Structure B and Structure C are eluted in this order, which facilitates the separation. Chromatographic conditions such as types of packed material, eluent, elution velocity, pressure and temperature are adjusted properly. It is also advantageous to prepare a derivative of a certain substance contained in the mixture of the sphingoglycolipid using a reagent that specifically reacts with that substance, and run the separation using chemical or physical properties of such derivative.
Use of Sphingomonas paucimobilis generally yields sphingoglycolipids of formula (1) having as R1 structures A and B. Use of Sphingomonas capsulata generally yields sphingoglycolipids of formula (1) having as R1 structures A and C. Use of Sphingomonas adhaesiva generally yields sphingoglycolipids of formula (1) having as R1 structure A and D. Thus proper selection of the strain based on these findings will help obtaining desired sphingoglycolipids with a high efficiency.
It is also possible to synthesize Sphingoglycolipid of formula (1) by combining synthetic methods which have previously been known. Individual sphingoglycolipids given by formula (1) can be prepared by, for example, previously synthesizing the sugar and sphingosine portions, and then forming an amide bond therebetween.
The following paragraphs details the external composition for skin commonly provided from the first, second and third aspects of the present invention.
There is no limitation on the morphology of the external composition for skin of the invention. Thus any form of solid, liquid, paste, jelly or powder is acceptable. It is possible to accomplish such forms by, for example, solidification with an aid of gellation agent, dispersion using liquid, solubilization by adding solvent, or pulverization through spray drying.
The external compositions for skin of the invention have excellent moisturizing and skin roughness preventing effects and is confirmed that it can provide appropriate moisture to skin surface to retain its smoothness. That is, the external compositions for skin of the invention can retain the moisture of skin for an extended period. Such effects are much superior to those of gangliosides or galactocerebrosides, also both of which are sphingoglycolipids with accepted moisturizing effect. Thus the external composition for skin of the invention can prove its merits in applications where improvements in skin roughness and keratin conditions, or skin protection is required.
The external composition for skin of the invention also has anti-atopic activity, allowing it to be applied to prevention and therapy of atopic dermatitis.
The external composition for skin of the invention is available, for example, as a cosmetic or medicine. Possible applications include toilet soap, shampoo, cleansing foam, rinse, eye cream, eye shadow, cream or milky lotion, toilet lotion, perfume, face powder, facial oil, hair-care cosmetics, hair dye, jelly fragrance, powder, pack, shaving cream, shaving lotion, suntan oil, anti-suntan oil, suntan lotion, sun-screening lotion, suntan cream, sun-screening cream, foundation, powdery fragrance, cheek rouge, mascara, eyebrow pencil, nail cream, nail enamel, nail enamel remover, hair cleaner, bath cosmetics, lipstick, lip cream, eyeliner, toothpaste, deodorant agent, eau de cologne, hair tonic, or hair restorer. The external composition for skin of the invention can also successfully be used as an ointment or wet pack.
The external composition for skin of the invention can contain various components besides sphingoglycolipids according to purposes of its use. Appropriate components can be added to enhance emollient property, to improve feeling, to reduce dryness after use, to improve solubility, to improve emulsifying property, to improve emulsion stability, to improve compatibility with oily components, to reduce stretched sense after use, to improve adhering to skin, to improve spreadability on skin, to reduce stickiness, to prevent skin roughness, to enhance skin refining effect, to enhance skin protection effect, to improve horny layer, to normalize epidermal keratinization (prevention of partial keratinization due to turnover acceleration, prevention of epidermal thickening, suppression of disorder in epidermal lipid metabolism), to moderate xeroderma such as senile xeroderma, to improve dried skin conditions such as chapping and scaling, to suppress wrinkles formation, to remove wrinkle, to heal wounds, to prevent and improve pigmentation, to delay aging, to reduce dandruff and itch, to relieve depilation, to prevent and heal scalp disease, to improve storability, to retrieve softness, to retrieve flexibility, to provide gloss, to suppress melanin production, and to prevent suntan.
Possible additives for the external compositions for skin of the invention include, for example, oil and fat components, phospholipid, UV absorber, infrared absorber, emulsifier, surfactant, aseptic agent, mildewproof agent, antioxidant, whitening agent, vitamin, amino acid, hormone, peptide, bioactive plant extract, fluorescent material, pigment, dye, perfumery, scrub material, metal ion blocker, binder, filler, thickener, saccharide, nutrient, pH adjuster, chelating agent, sterilizer, keratin conditioner, keratin solubilizer, antibiotic, dermal permeation accelerator, circulation accelerator, antiphlogistic, cell activator, anti-inflammatory, anodyne, emollient agent, skin relaxing agent, traumatic remedy, metabolic accelerator, all of which are compoundable depending on purposes. It is also allowable to add moisturizing components other than active components of the invention.
Oil and fat components compoundable with the external composition for skin of the invention include fatty acids (e.g. oleic acid, behenic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, linoleic acid, γ-linolenic acid, cholumbinic acid, eicosa-(n-6,9,13)-trienic acid, arachidonic acid, α-linolenic acid, Tymnodonic acid, and hexaenic acid), ester oils (e.g. pentaerythritol-tetra-2-ethyl hexanoate, isopropyl myristate, butyl stearate, hexyl laurate, octyldodecyl myristate, diisopropyl adipate and diisopropyl sebacate), waxes (e.g. beeswax, whale wax, lanoline, carnauba wax, candelilla wax and vaseline), animal and plant oils (e.g. mink oil, olive oil, castor oil, cocoa butter, palm oil, cod-liver oil, beef tallow, butter, evening primrose oil rice bran oil and squalane), mineral oils (e.g. hydrocarbon oils and liquid paraffin), silicone oils (e.g. metylphenyl silicone and dimethyl silicone), higher alcohols (e.g. lauryl alcohol, stearyl alcohol, oleyl alcohol, cetyl alcohol, 2-octyl dodecanol and 2-decyltetradecanol) and their derivatives. Allowable organic acids include α-hydroxylic acid, hydroxycarboxylic acid, dicarboxylic acid, glycyrrhizic acid, glycyrrhetinic acid and mevalonic acid (mevalonolactone).
Phospholipids compoundable with the external composition for skin of the invention include glycerophospholipids of the monoacyl ester type or diacyl ester type. They are enumerated as lysophosphatidyl choline, lysophosphatidyl ethanolamine, lysophosphatidyl serine, lysophosphatidyl inositol, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine, phosphatidyl glycerol, phosphatidic acid and sphingomyelin. Natural source lecithin (e.g. yolk) and hydrogenated compounds of the substances listed above are also available.
UV absorbers compoundable with the external compositions for skin of the invention typically include oxybenzone (2-hydroxy-4-methoxybenzophenone), oxybenzonesulfonic acid, oxybenzone-sulfonic acid (trihydrate), guaiazulene, ethylene glycol salicylate, octyl salicylate, dipropylene glycol salicylate, phenyl salicylate, homomentyl salicylate, methyl salicylate, methyl diisopropyl cinnamate, cinoxate (p-methoxycinnamic acid 2-ethoxyethyl ester), di-p-methoxycinnamic acid mono-2-ethyl-hexylacid glyceryl, dihydroxymethoxybenzophenone, dihydroxy-methoxybenzophenone sodium disulfonate, dihydroxybenzophenone, tetrahydroxy-benzophenone, p-aminobenzoic acid, ethyl p-amino-benzoate, glyceryl p-aminobenzoate, amyl p-dimethylbenzoate, 2-ethylhexyl p-aminobenzoate, p-hydroxyanisole, 2-ethylhexyl-p-methoxycinnamate, isopropyl-p-methoxycinnamate, di-isopropyl cinnamate, 2-(2-hydroxy-5-methylphenyl)benzotriazole, sodium hydroxymethoxybenzophenone sulfonate, 4-tert-butyl-4′-methoxybenzoylmethane, 2-ethylhexyl salicylate, glyceryl-p-aminobenzoate, methyl-o-aminobenzoate, 2-hydroxy-4-methoxybenzophenone, amyl-p-dimethylaminobenzoate, 2-phenylbenzoimidazole-5-sulfonate, 2-hydroxy-4-methoxybenzophenoneimidazole-5-sulfonate, 2-hydroxy-4-methoxybenzophenone-5-sulfonate, digalloyltrioleate, p-methoxysilicocarbonate-2-ethoxyethyl, butylmethoxybenzoyl-methane, glyceryl-mono-2-ethylhexanoyl-di-p-methoxy-benzophenone, 2-ethylhexyl-2-cyano-3,3′-diphenylacrylate, 2,2′-dihydroxy-4-methoxybenzophenone, and ethyl-4-bishydroxy-propylamino-benzoate.
Emulsifiers and surfactants compoundable with the external compositions for skin of the invention include nonionic surfactants, anionic surfactants and cationic surfactants.
As the nonionic surfactants enumerated are sorbitan ester (e.g. sorbitan monolaurate, sorbitan monooleate, sorbitan monoisostearate), polyoxyethylene sorbitan ester (e.g. polyoxyethylene sorbitan monoisostearate, polyoxyethylene sobitan monolaurate, polyoxyethylene sorbitan monooleate), glycerol esters (e.g. glycerol monoisostearate, glycerol monomyristate), polyoxyethylene glycerol ether (e.g. polyoxyethylene glycerol monoisostearate, polyoxyethylene glycerol monomyristate), polyglycerin fatty acid ester (e.g. diglyceryl monostearate, decaglyceryl decaisostearate, diglyceryl diisostearate), glycerin fatty acid esters (e.g. glyceryl monocaprate, glyceryl monolaurate, glyceryl monomyristate, glyceryl monopalmitate, glyceryl monooleate, glyceryl monostearate, glyceryl monolinoleate, glyceryl monoisostearate, glyceryl monodilinoleate, glyceryl monodicaprate), polyoxyethyleneglycerin fatty acid esters (e.g. polyoxyethyleneglyceryl monomyristate, polyoxyethyleneglyceryl monooleate, polyoxyethyleneglyceryl monostearate), polyoxyethylene branched alkyl ethers (e.g. polyoxyethylene octyl dodecyl alcohol, polyoxyethylene-2-decyl tetradecyl alcohol), polyoxyethylene alkyl ether (e.g. polyoxyethylene oleyl alcohol ether, polyoxyethylene cetyl alcohol ether), polyoxyethylene hydrogenated castor oil fatty acid ester (e.g. polyoxyethylene hydrogenated castor oil, polyoxyethylene dihydrocholesterol ether, polyoxyethylene hydrogenated castor oil isostearate), and polyoxyethylene alkyl aryl ether (e.g. polyoxyethylene octylphenol ether).
The anionic surfactants are enumerated as salts (e.g. diethanolamine salt, triethanolamine salt, amino acid salt, potassium salt, sodium salt) of higher fatty acids (e.g. oleic acid, stearic acid, isostearic acid, palmitic acid, myristic acid, behenic acid), ethercarboxylic acid alkaline salts, N-acylamino acid salts, N-acylsalcone salts, and higher alkyl sulfonic acid salts.
Typical cationic surfactants and ampholytic surfactants are alkyl quaternary ammonium salts, polyamine, and alkylamine salts.
Powdery agents compoundable with the external compositions for skin of the invention include talc, kaolin, fuller's earth, rubber, starch, silica, silicic acid, aluminum slicate hydrate, chemically modified aluminum magnesium silicate, sodium polyacrylate, tetraalkylaryl snuctite, trialkylarylammonium snuctite, ethylene glycol monostearate, sodium carboxymethylcellulose, carboxyvinyl polymer, chalk, gum, ethylene glycol monostearate, and ethylene glycol distearate.
Polyols compoundable with the external compositions for skin of the invention include polyglycerins such as glycerin, diglycerin, triglycerin or tetraglycerin; ethylene glycol, propylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, dipropylene glycol, polyethylene glycol, sorbitol, erythritol, maltotriose, threitol, sucrose, glucose, maltose, multitose, fructose and xylitose.
Other materials compoundable with the external composition for skin of the invention include vitamins (e.g. vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K), amino acids (e.g. proline, leucine, isoleucine, alanine, threonine, lysine, cysteine, arginine), hormones (e.g. estrogen, pregnenolone, adrenal cortex hormone), peptides (e.g. keratin, collagen, elastin), saccharides (those listed above in the section for polyol), inorganic salts (e.g. sodium chloride, sodium hydrogen carbonate, sodium carbonate, borax, sodium sulfate, sodium sulfide, sodium thiosulfate, sodium sesquicarbonate, magnesium oxide, calcium carbonate, magnesium carbonate, potassium chloride, potassium sulfide), cultured lactic acid bacteria, sterols (e.g. cholesterol, provitamin D3, campesterol, stigmastanol, stigmasterol, 5-dihydrocholesterol, α-spinasterol, cholesterol fatty acid ester), sphingosines (e.g. sphingosine, dihydrosphingosine, phytosphingosine, dehydrosphingosine, dehydrophytosphingosine, sphingadienine), ceramide, pseudoceramide, saponin, chitin derivatives, oligosaccharides (e.g. maltose, xylobiose, isomantose, lactose, sucrose, raffinose, maltotriose, xylotriose, maltotetraose, xylotetraose, maltopentaose, xylopentaose, maltohexaose, xylohexaose, maltoheptaose, xyloheptaose), acidic mucopolysaccharides (hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparin, heparan sulfate), and yeast extract.
Still other materials compoundable with the external composition for skin of the invention include thickeners (e.g. carboxyvinyl polymer, carboxymethylcellulose, polyvinyl alcohol, carrageenan, alginate, arginic acid propylene glycol ester, gelatin, electrolytes such as sodium chloride), whitening agent (e.g. arbutin, allantoin, vitamin E derivatives, glycyrrhizin, ascorbic acid phosphoric acid magnesium salt, Kojic acid, panteric acid derivative, placenta extract, coix seed, green tea, pueraria root, mulberry bark, licorice, scutellaria root, aloe, bitter orange peel, German chamomile, Ganoderma lucidum), skin protectors (e.g. retinol, retinol ester, retinoic acid), skin emollient agents (e.g. stearyl alcohol, glyceryl monoricinoleate, mink oil, cetyl alcohol, stearic acid, palm oil, castor oil, oxostearic acid), skin relaxing agents (e.g. stearyl alcohol, glycerin monoricinoleate, glycerin monostearate, cetyl alcohol), skin permeation accelerator (e.g. 2-methylpropane-2-ol, 2-propanol, ethyl-2-hydroxypropanoate, 2,5-hexanediol, acetone, tetrahydrofuran), biologically active plant extracts (e.g. extracts from aloe, arnica, licorice, sage or swertia herb), preservatives (e.g. p-hydroxybenzoate, sodium benzoate, urea, metylparaben, ethylparaben, propylparaben, butylparaben), agents (e.g. α-tocopherol, butylhydroxytoluene), buffers (e.g. combination of lactic acid with triethanolamine or sodium hydroxide), keratin solubilizers (e.g. lactic acid, glycolic acid, malic acid, tartaric acid, citric acid), scrubbing materials (e.g. polyethylene powder), and pigments (e.g. lake of calcium, barium or aluminum, iron oxide, titanium dioxide, mica).
It is also possible to add other materials to the external compositions for skin of the invention as required. The amount and method of addition of each component can properly be based on methods known in this technical area.
The external compositions for skin of the invention are widely used in the field where moisturizing and anti-atopic effects are required. The amount of use will be determined so that the desired moisturizing effect is fully achieved.
This invention will be detailed hereinafter referring to the several preferred embodiments. Components, ratios and procedures shown in these embodiments can properly be altered without departing from the spirit of the invention. Thus the scope of the invention is not limited to the following embodiments.
EXAMPLE 1 Obtaining White Bacteria
A medium containing 1.0% glucose, 0.5% yeast extract and 0.2% sodium glutamate (adjusted to pH 7.0 with citric acid) was put into a 500-ml conical flask, and a strain of genus Sphingomonas (IAM 12576) was then added. The content was cultured under shaking using a shaker at 30° C. for 20 hours. The medium was thoroughly removed and another 50 ml of medium with the above composition was newly added, which was again cultured under shaking using a shaker at 30° C. for 20 hours. After repeating such combination of medium exchange and culture ten times, the obtained culture liquor was diluted and sprayed on a plate medium with the above composition. From this culture liquor, Sphingomonas paucimobilis KFC-W-1 (Deposition Nos. FERM P-16238 and BP-6368) was found and collected (at a frequency of 1/109 cells).
A similar procedure, except that using a strain of genus Sphingomonas derived from rice plant as an initial strain in place of Sphingomonas strain (IAM 12576), yielded Sphingomonas paucimobilis MK-253W (Deposition Nos. FERM P-16693 and BP-6369), a white mutant strain.
A similar procedure, except that using still another strain of genus Sphingomonas derived from rice plant as an initial strain, yielded Sphingomonas paucimobilis MK-254W (Deposition Nos. FERM P-16694 and BP-6370), a white mutant strain.
A similar procedure, except that using a strain of genus Sphingomonas derived from Deccan grass as an initial strains yielded Sphingomonas paucimobilis MK-332W (Deposition Nos. FERM P-16695 and BP-6371), a white mutant strain.
Obtained white mutant strains and initial strains (IAM 12576) were identified according to “A Guide for Medical Bacterial Identification (3rd edition)”. Results were listed in the tables below.
TABLE 1
S. Initial
pauci- Strain KFC MK- MK- MK-
Tested Items mobilis IAM12576 W-1 253W 254W 332W
Mobility + + + + + +
Growth at + + + + + +
37° C.
Growth at + + + + + +
20-22° C.
(25° C.)
Brown dye
Purple dye
Green dye
Yellow dye + +
Orange dye
Growth on
Macconkey's
agar
Oxidase d
(kovacs)
Oxidation d
on O-F
medium
Alkalization
on O-F
medium
Reduction of
nitrate to
nitrite
Simmons'
citric acid
agar
Christen- d + +
sen's citric
acid agar
Urease
Gelatinase
H2S
(lead acetate + + +
paper)
(vial tube)
Gluconic salt
Malonic salt
Carbohy-
drate, acid;
10% Glucose
10%
Galactose
Peptone
aquamedi-
um, acid;
Glucose
Ammonium
salt agar,
acid;
Glucose + + + + + +
Arabinose + + + + + +
Cellobiose + + + + + +
Ethanol + + + + + +
Fructose + + + + + +
Glycerin + + + + + +
Inositol
Galactose + + + + + +
Maltose + + + + + +
Mannitol
TABLE 2
S. Initial
pauci- Strain KFC MK- MK- MK-
Tested Items mobilis IAM12576 W-1 253W 254W 332W
Ammonium
salt
agar, acid;
Raffinose + + + + + +
Rhamnose + + + + + +
Salicin + + + + + +
Sorbitol
Sucrose + + + + + +
Trehalose + + + + + +
Xylose + + + + + +
Phenyl- d
alanine
Arginine
dihidrase
Lysine
decar-
boxylase
Ornithine
decar-
boxylase
Selenic
salt
reduction
Casein
hydrolysis
DNase + + + + + +
(HCl
method)
Thomley
arginine
Tween 20 + + +
hydrolysis
Tyrosine + + + + + +
hydrolysis
Brown dye d + + + + +
production
on tyrosine
agar medium
Nitrite
reduction
Growth on + + + + + +
PHBA
Endogenous + + + + + +
PHBA
accumulation
Fluorescent
dye
production -
King B agar
Growth
at 5° C.
Growth at d
42° C.
(40° C.)
3-Keto-
lactose
production
Lecithinase
Starch d + + + + +
hydrolysis
Christen-
sen's urea
Acylamidase
Indole
production
Acetyl-
methyl-
carbinol
production
EXAMPLE 2 Proliferation Tests Using Various Media
Various media shown in the table below were adjusted to pH 7.0 using citric acid, which was followed by sterilization. Sphingomonas paucimobilis KFC-W-1 was then cultured in these media at 30° C. under shaking using a shaker. Status of bacteria proliferation was confirmed after 24 hours.
TABLE 3
Medium Yeast Sodium
No. Glucose extract Glutamate Other components
1 1.0 0.5 0.2 None
2 1.0 None
3 1.0 None
4 1.0 Peptone
5 1.0 Meat extract
6 1.0 None
7 0.5 None
8 1.0 0.2 None
9 1.0 0.5 NH4Cl
10  1.0 0.2 (NH4)2SO4
11  3.0 0.1 NH4Cl
0.1 (NH4)2SO4
0.05 K2HPO4
0.05 MgSO4.7H2O
0.05 KCl
0.001 FeSO4.7H2O
12  1.0 0.5 0.5 Casamino acids
0.2 (NH4)2SO4
0.1 MgSO4
0.2 K2HPO4
(Unit: wt %)
No significant proliferation of bacteria was observed for media 2, 6, 7, 8, 9 and 10. Medium 11 showed a small extent of proliferation, and media 3, 4 and 5 exceeded it. A still larger extent of proliferation was observed for medium 12, whereas medium 1 showed an exceptionally large extent of proliferation apparently exceeding all of the others.
Same experiments in media 1 having its sodium glutamate concentration altered to 0.1%, 0.5% or 0.8%, respectively, showed that the 0.1% medium can allow proliferation as large as that attained by the 0.2% medium.
Sodium glutamate in medium 1 was then replaced with L-ornithine hydrochloride, glycine, L-leucine, L-methionine, L(+)-lysine hydrochloride, L-cyctein hydrochloride hydrate, L-glutamic acid, L-tryptophan and DL-phenylalanine, respectively, and again similar experiments were performed. It was observed that glycine and L-glutamic acid can cause a proliferation at a level comparable to that for sodium glutamate.
EXAMPLE 3 Preparation of Sphingoglycolipid-Containing Composition
The white bacteria obtained as decribed in Example 1 were cultured at room temperature for 24 hours. The culture was run using a medium containing 1.0% glucose, 0.5% yeast extract and 0.2% sodium glutamate (adjusted to pH7.0 with citric acid) under aeration at 0.7 vvm.
After sterilizing the resulted culture liquor and adjusting its pH at 5.0, the bacterial bodies were collected by centrifugation. Twenty kg of the bacterial bodies were then added to 30 liters of acetone, stirred, and collected by filtration. Thus obtained bacterial bodies were extracted three times with 30 liters each of acetone, and resultant extracts were distilled using a flash evaporator to remove the solvent. Four liters of residual liquor is added with 8 liters of acetone, stirred, and allowed to stand for precipitation. The precipitate was collected, added with another 2 liters of acetone, and again allowed to stand to produce the precipitate. The precipitate was finally collected, dewatered, and dried under reduced pressure to prepare the white composition comprising sphingoglycolipid.
EXAMPLE 4 Preparation of Sphingoglycolipid-Containing Composition
Sphingomonas paucimobilis (IAM12576) was cultured at room temperature for 24 hours. The culture was run using a medium containing 1.0% glucose, 0.5% yeast extract and 0.2% sodium glutamate (adjusted to pH7.0 with citric acid) under aeration at 0.7 vvm.
After sterilizing the resulted culture liquor and adjusting its pH at 5.0, the bacterial bodies were collected by centrifugation. Twenty kg of the fungus body was then added with 30 liters of acetone, stirred, and collected by filtration. Thus obtained bacterial bodies were extracted three times with 30 liters each of solvent shown in Table 4, and the resultant extracts were distilled using a flash evaporator to remove the solvent. Four liters of residual liquor is added with 8 liters of acetone, stirred, and allowed to stand for precipitation. The precipitate was collected, added with another 2 liters of acetone, and again allowed to stand to produce the precipitate. The precipitate was finally collected, dewatered, and dried under reduced pressure to prepare the composition comprising sphingoglycolipid (Samples 1 to 19).
TABLE 4
Sample Mixing
No. Solvents ratio
 1 Methanol
 2 Methanol/water 85/15
 3 Methanol/water 70/30
 4 Methanol/water 55/45
 5 Ethanol
 6 Ethanol/water 85/15
 7 Ethanol/water 70/30
 8 Ethanol/water 55/45
 9 Propanol
10 Propanol/water 85/15
11 Propanol/water 70/30
12 Propanol/water 55/45
13 Isopropanol
14 Isopropanol/water 85/15
15 Isopropanol/water 70/30
16 Isopropanol/water 55/45
17 Butanol
18 Butanol/water 85/15
19 Methanol/chloroform 75/25
Findings from a compositional analysis of sphingoglycolipid of Sample 1 are shown in Table 5.
TABLE 5
Components Values
Heavy metal 20 ppm or less
Arsenic 2 ppm or less
Acid value 30 or less
Iodine value 20 to 30
Sphingosine 13.0 to 18.0
EXAMPLES 5-25 Production of External Compositions for Skin
As the active components used in the following Examples 5 to 25, sphingoglycolipid-containing compositions prepared in Examples 3 and 4, and at least one active component selected from a group listed below (represented by formula (1) where R3 for all the components is a straight alkyl group having 12 carbon atoms).
TABLE 6
Active weight
component R1 R2 part
 1 A a 1.00
 2 A b 1.00
 3 A c 1.00
 4 B a 1.00
 5 B b 1.00
 6 B c 1.00
 7 C a 1.00
 8 C b 1.00
 9 C c 1.00
10 D a 1.00
11 D b 1.00
12 D c 1.00
13 A a 0.50
A b 0.50
14 B a 0.50
B b 0.50
15 A a 0.50
B a 0.50
16 A b 0.50
B b 0.50
17 A a 0.25
B a 0.25
C a 0.25
D a 0.25
18 A b 0.25
B b 0.25
C b 0.25
D b 0.25
19 A a 0.45
A b 0.45
A c 0.10
20 B a 0.45
B b 0.45
B c 0.10
21 C a 0.20
C b 0.40
C c 0.40
22 D a 0.20
D b 0.40
D c 0.40
EXAMPLE 5 Production of a Toilet Milky Lotion
A first liquid prepared by mixing individual components listed below at 75° C. was added to a second liquid prepared by mixing individual components listed below at 75° C., and then thoroughly emilsified at 75° C. to produce a toilets milky lotion.
TABLE 7
Components weight part
(First liquid)
Squalane 4.9
Monostearic acid 1.8
Vaseline 1.2
Butylparaben 0.1
Liquid paraffin 5.0
(Second liquid)
Active component 1.0
Sodium cetylsulfate 0.8
Methylparaben 0.2
Purified water 85.0 
EXAMPLE 6 Production of a Toilet Lotion
Individual components listed below were mixed at room temperature and thoroughly stirred to produce a toilet lotion.
TABLE 8
Components weight part
Active component 1.0
Methylparaben 0.1
Polyoxyethylene hydrogenated castor oil 1.2
Polyoxyethylene sorbitol oleate 0.4
Ethanol 5.3
Purified water 92.0 
EXAMPLE 7 Production of a Powder Foundation
Individual components listed below were mixed at room temperature and thoroughly stirred to produce a powder foundation.
TABLE 9
Components weight part
Active component 1.0
Mica 37.8 
Talc 20.0 
Titanium dioxide 12.0 
Kaolin 5.0
Iron oxide 3.5
Powdered Nylon 8.0
Octyldodecyl myristate 2.0
Neopentylglycol diisooctate 2.0
Sorbitol monooleate 0.5
Zinc stearate 1.0
Red oxide 1.0
Squalane 6.0
Aseptic agent 0.1
Antioxidant 0.1
EXAMPLE 8 Production of a Whitening Powder
Individual components listed below were mixed and ground at room temperature to produce a whitening powder.
TABLE 10
Components weight part
Active component 20.0
Sucrose 50.0
Polyethylene glycol 10.0
Silica  4.5
Vitamin C  5.0
Vitamin C dipalmitate 10.0
Dye  0.5
EXAMPLE 9 Production of an Emollient Cream
From the components listed below, 1,3-butylene glycol and purified water were first mixed and heated to 70° C., to which a molten mixture of the residual components was added, which was followed by homogenizing the emulsified particles using a homomixer and cooled to produce a emollient cream.
TABLE 11
Components weight part
Active component 5.0
Stearyl alcohol 6.0
Stearic acid 2.0
Hydrogenated lanoline 4.0
Squalane 9.0
Octyldodecanol 10.0 
POE(25)cetyl alcohol ether 3.0
glycerin monostearate 2.0
1,3-butylene glycol 10.0 
Dye 0.5
Aseptic agent 0.1
Antioxidant 0.1
Purified water 48.3 
EXAMPLE 10 Production of a Pre-Shaving Lotion
Individual components listed below were mixed at room temperature and thoroughly stirred to produce a pre-shaving lotion.
TABLE 12
Components weight part
Active component 1.0
Zinc sulfophenolate 1.0
Isopropylmyristic acid ester 7.0
Isopropylpalmitic acid ester 8.0
Ethanol 82.5 
Perfume 0.5
EXAMPLE 11 Production of a Cleansing Foam
From the components listed below, palmitic acid, myristic acid, lauric acid, palm oil and aseptic agent were melted by heating and kept at 70° C., to which a mixture of potassium hydroxide and purified water was added, which was followed by adding the residual components and thorough stirring, to produce a cleansing foam.
TABLE 13
Components weight part
Active component 4.5
Stearic acid 10.0 
Palmitic acid 10.0 
Myristic acid 12.0 
Lauric acid 4.0
Palm oil 2.0
Potassium hydroxide 6.0
Glycerol monostearic acid ester 2.0
POE(20) Sorbitol monostearate 2.0
Dye 0.5
Aseptic agent 0.1
Chelating agent 0.2
Purified water 46.7 
EXAMPLE 12 Production of a Pack
From the components listed below, titanium oxide and talc were thoroughly dispersed in purified water, to which sorbitol was added and heated to 70° C. to be dissolved, then the residual components were added and thoroughly stirred, which was followed by degassing and cooling to produce a pasty pack.
TABLE 14
Components weight part
Active component 4.5
Polyvinyl acetate emulsion 15.0 
Polyvinyl alcohol 10.0 
Jojoba oil 2.0
Squalane 2.0
POE sorbitol monostearic acid ester 1.0
Titanium oxide 5.0
Talc 10.0 
Sorbitol 10.0 
Ethanol 8.0
Dye 0.5
Aseptic agent 0.2
Purified water 31.8 
EXAMPLE 13 Production of a Lipstick
Individual components listed below previously heated at 70° C. were mixed, thoroughly stirred, poured into a mold and cooled rapidly to produce a lipstick.
TABLE 15
Components weight part
Active component 2.0
Castor oil 25.0 
Cetyl 2-Ethylhexanate 20.0 
Lanoline 10.0 
Isopropylmyristic acid ester 10.0 
Candelilla wax 9.0
Solid paraffin 8.0
Carnauba wax 5.0
Beeswax 5.0
Titanium dioxide 5.0
Dye 1.0
EXAMPLE 14 Production of a Lip Cream
From the components listed below, active component, stearic acid, stearyl alcohol and butyl stearate, each of which was previously heated to 70° C., were mixed together, the residual components were added, and thoroughly stirred to produce a lip cream.
TABLE 16
Components weight part
Active component 4.0
Stearic acid 14.0 
Stearyl alcohol 8.0
Butyl stearate 10.0 
Propylene glycol 10.0 
Glycerin monostearate 4.0
Potassium hydroxide 1.0
Antioxidant 0.2
Purified water 48.8 
EXAMPLE 15 Production of a Cheek Rouge
Individual components listed below, except perfume and liquid paraffin, were mixed at room temperature, then the mixture was sprayed with the perfume and the liquid paraffin, which was followed by grinding and compression molding to produce a cheek rouge.
TABLE 17
Components weight part
Active component 1.5
Talc 77.8 
Kaolin 9.0
Zinc myristate 5.0
Pigment 3.0
Liquid paraffin 3.0
Perfume 0.5
Aseptic agent 0.2
EXAMPLE 16 Production of an Eyeliner
From the components listed below, carbon black previously ground was dispersed in purified water, the residual components were added, and the mixture was stirred at room temperature to produce an eyeliner.
TABLE 18
Components weight part
Active component 10.0 
Carbon black 5.0
Polyoxyethylene dodecyl ether 2.0
Dye 0.5
Aseptic agent 0.2
Purified water 82.3 
EXAMPLE 17 Production of a Mascara
From the components listed below, purified water and polyacrylic acid ester emulsion were mixed at 70° C., the residual components previously mixed by heating at 70° C. were then added, which was followed by emulsifying dispersion to produce a mascara.
TABLE 19
Components weight part
Active component 4.5
Iron oxide 10.0 
Polyacrylic acid ester emulsion 27.0 
Liquid paraffin 8.0
Lanoline wax 8.0
Lightweight isoparaffin 28.0 
Sorbitol sesquioleate 4.0
Dye 0.5
Antioxidant 0.1
Aseptic agent 0.1
Purified water 9.8
EXAMPLE 18 Production of an Eyebrow Pencil
Individual components listed below except powdery ones were melted and mixed, then the powdery components were added, which was followed by kneading and molding to produce an eyebrow pencil.
TABLE 20
Components weight part
Active component 1.0
Iron oxide 19.0 
Titanium oxide 5.0
Talc 10.0 
Kaolin 15.0 
Japan tallow 20.0 
Stearic acid 10.0 
Beeswax 5.0
Hydrogenated castor oil 5.0
Vaseline 4.0
Lanoline 3.0
Liquid paraffin 2.8
Antioxidant 0.1
Aseptic agent 0.1
EXAMPLE 19 Production of a Hand Cream
Individual components listed below were mixed by heating at 70° C., then thoroughly stirred to produce a hand cream.
TABLE 21
Components weight part
Active component 3.0
Glycerin 20.0 
Urea 2.0
Stearic acid monoglyceride 2.5
Vaseline 6.0
Liquid paraffin 10.0 
Purified water 56.5 
EXAMPLE 20 Production of a Hair Shampoo
Individual components listed below were mixed by heating at 70° C., then thoroughly stirred to produce a hair shampoo.
TABLE 22
Components weight part
Active component 5.0
Glycerin 1.0
Sodium laurylpolyoxyethylene sulfate 10.0 
Sodium lauryl sulfate 6.0
Palm oil fatty acid diethanolamide 3.0
Metal ion blocker 0.1
pH Adjuster 0.5
Aseptic agent 0.2
Purified water 74.2 
EXAMPLE 21 Production of a Hair Rinse
Individual components listed below were mixed by heating at 70° C., then thoroughly stirred to produce a hair rinse.
TABLE 23
Components weight part
Active component 3.0
Silicone oil 2.8
Liquid paraffin 1.2
Glycerin 2.5
Cetyl alcohol 1.3
Stearyl alcohol 1.1
Stearyl chloride trimethylammonium 0.6
Dye 1.0
Aseptic agent 0.2
Purified water 86.3  
EXAMPLE 22 Production of a Hair Liquid
Individual components listed below were mixed at room temperature to produce a hair liquid.
TABLE 24
Components weight part
Active component  1.0
Polyoxypropylene butyl ether 20.0
Polyoxyethylene hardened castor oil  1.0
Ethyl alcohol 50.0
Perfume  0.5
Purified water 27.5
EXAMPLE 23 Production of a Hair Dye
Individual components listed below were mixed at room temperature to produce a hair dye.
TABLE 25
Components weight part
Active component 3.0
Pigment 1.0
Acrylic resin alkanolamine (50%) 8.0
Perfume 0.5
Ethyl alcohol 88.0 
EXAMPLE 24 Production of Bath Salts
Individual components listed below were mixed at room temperature to produce bath salts.
TABLE 26
Components weight part
Active component 10
Sodium sulfate 50
Sodium hydrogencarbonate 25
Sodium chloride 13
Dye  2
EXAMPLE 25 Production of an Anti-Atopic Ointment
Individual components listed below were emulsified and dispersed at 70° C., and cooled to produce an anti-atopic ointment.
TABLE 27
Components weight part
Composition of Example 7 3.0
Vaseline 24.0 
Stearyl alcohol 21.0 
Propylene glycol 13.0 
Polyoxyethylene hardened castor oil 3.5
Glycerin monostearate 1.0
Aseptic agent 0.2
Purified water 34.3 
TEST EXAMPLE
Test for Evaluating Moisturizing and Skin Roughness Prevention Effects
Twenty male hairless mice of 9-week old (Skh:hr-1, Nihon SLC) were treated with 0.5% Triton X-150 (50 μl) in a circular area of 2.5 cm diameter on their rear backs. The once-a-day application was continued for 5 days. On the 6th day and thereafter, middle-wavelength UV light was irradiated at a dose of 0.15 J/cm2 using a SE lamp (manufactured by Toshiba Medical Instruments Co., Ltd.), and Samples 1 to 5 (dissolved in 0.5% Triton X-150) listed below and control sample (0.5% Triton X-150) were applied. These procedures were followed once a day and continued up to the 10th day. Five hairless mice were subjected to each test for Samples or the control.
TABLE 28
Concentration of
Sample No. Active component active component
Sample 1 (invention) No. 19 in Table 6 1.0%
Sample 2 (invention) No. 20 in Table 6 0.1%
Sample 3 (comparison) Glyceroglycolipid 1.0%
Sample 4 (comparison) Ganglioside 1.0%
Sample 5 (comparison) Galactocerebroside 1.0%
After the middle-wavelength UV irradiation and the sample application were completed on the 10th day, amount of transcutaneous transpiration was measured using a hydrograph (model AMU-3: manufactured by Fauchon Co., Ltd.) to determine an average value for the five mice. Results were shown in the table below, where the values are expressed in relative values assuming the control (9 g/m2/h) as 100.
TABLE 29
Relative
transcutaneous
Sample No. transpiration
Control 100 
Sample 1 (invention) 64
Sample 2 (invention) 79
Sample 3 (comparison) 123 
Sample 4 (comparison) 89
Sample 5 (comparison) 91
From these findings, it was made clear that the Samples of this invention allow only quite a low level of transcutaneous transpiration, proving their excellent moisture retaining effect. In the visual observation of the rear backs of the hairless mice after the completion of 10-day tests, there was no sign of skin roughness by the application of the Samples of the present invention unlike the comparative Samples.
These potent moisturizing and skin roughness preventing effects were observed also for other compositions not described in the above Examples. In particular, a sphingoglycolipid prepared from each white bacterium according to the method described in Example 3, and Samples 1, 11, 12, 15, 16 and 18 prepared according to the method described in Example 4 showed exceedingly potent moisturizing and skin roughness preventing effects.

Claims (23)

What is claimed is:
1. An external composition for skin comprising a component extracted from a white bacterium of the genus Sphingomonas, said extract being substantially uncolored,
wherein said component is obtained by washing said white bacterium of the genus Sphingomonas with acetone, and then extracting the resultant with alcohol or alcohol-water mixture.
2. An external composition for skin according to claim 1 wherein said component extracted from a white bacterium of the genus Sphingomonas comprises a sphingoglycolipid represented by the following formula:
Figure US06348201-20020219-C00005
where, R1 represents a sugar portion consisting of a single uronic acid or one to four hexoses selected from a group consisting of uronic acid, glucosamine, galactose and mannose; R2 represents an alkyl group which may have a cycloalkyl group, an algenyl group or an alkynyl group; and R3 represents an alkyl group; these alkyl, algenyl and alkynyl groups being straight or branched, and substituted or unsubstituted.
3. A method of using said external composition for skin as claimed in claim 1 as a toilet soap, shampoo, cleansing foam, rinse, eye cream , eye shadow, cream or milky lotion, toilet lotion, perfume, face powder, facial oil, hair-care cosmetics, hair dye, jelly fragrance, powder, pack, shaving cream, shaving lotion, suntan oil, anti-suntan oil, suntan lotion, sun-screening lotion, suntan cream, sun-screening cream, foundation, powdery fragrance, cheek rouge, mascara, eyebrow pencil, nail cream, nail enamel, nail enamel remover, hair cleaner, bath cosmetics, lipstick, lip cream, eyeliner, toothpaste, deodorant agent, eau de cologne, hair tonic, hair restorer, ointment, wet pack, medicated lip cream or anti-atopic agent, comprising
applying said composition to skin, hair or fingernails.
4. The method of claim 3 wherein said sphingoglycolipid extracted from a white bacterium of the genus Sphingomonas is represented by the formula
Figure US06348201-20020219-C00006
wherein R1 represents a sugar portion of four hexoses consisting of a uronic acid, a glucosamine, a galactose and a mannose; three hexoses consisting of a uronic acid, a glucosamine and a galactose; or four hexoses consisting of a uronic acid, a galactose and two glucoses;
R2 represents an alkyl group which may have a cycloalkyl group, an algenyl group or an alkynyl group; and R3 represents an alkyl group; these alkyl, algenyl and alkynyl groups being straight or branched, and substituted or unsubstituted.
5. The method of claim 4 wherein said composition is a toilet soap, shampoo, cleaning foam or shaving cream.
6. The method of claim 4 wherein said composition further comprises a sunscreen, and said composition is a suntan oil, an anti-suntan oil, a suntan lotion, a sun-screening lotion, a suntan screen or a sun-screening cream.
7. A method for preparing an external composition for skin which comprises obtaining an extract of a white bacterium of the genus Sphingomonas, and mixing said extract with a cosmetically acceptable carrier.
8. A method for preparing an external composition for skin according to claim 7 wherein said extract is not subject to a decoloring process.
9. A method for preparing an external composition for skin according to claim 7 which comprises the steps of washing the white bacterium of the genus Sphingomonas with acetone and then extracting the resultant with alcohol or alcohol-water mixture.
10. A method for preparing an external composition for skin according to claim 9 wherein said alcohol or alcohol-water mixture is methanol, propanol-water mixture or butanol-water mixture.
11. A method for preparing an external composition for skin according to claim 10 wherein said alcohol or alcohol-water mixture is propanol-water mixture having a propanol content of 75 wt % or less, or butanol-water mixture having a butanol content of 95 wt % or less.
12. A method for preparing an external composition for skin according to claim 11 wherein said alcohol or alcohol-water mixture is butanol-water mixture having a butanol content ranging from 80 to 95 wt %.
13. A method for preparing an external composition for skin according to claim 7 wherein said external composition comprises a shingoglycolipid represented by the following formula:
Figure US06348201-20020219-C00007
where R1 represents a sugar portion consisting of a single uronic acid or one to four hexoses selected from a group consisting of uronic acid, glucosamine, galactose and mannose; R2 represents an alkyl group which may have a cycloalkyl group, an alkenyl group or an alkynyl group; and R3 represents an alkyl group; these alkyl, alkenyl and alkynyl groups being straight or branched, and substituted or unsubstituted.
14. A method for preparing an external composition for skin according to claim 13 wherein said R1 consists of 3 or 4 hexoses.
15. A method for preparing an external composition for skin according to claim 14 wherein said R1 is a sugar portion of four hexoses consisting of a uronic acid, a glucosamine, a galactose and a mannose; three hexoses consisting of a uronic acid, a glucosamine and a galactose; or four hexoses consisting of a uronic acid, a galactose and two glucoses.
16. A method for preparing an external composition for skin according to claim 13 wherein said R1 is represented by any one of the following formulae A to D:
Figure US06348201-20020219-C00008
17. A method for preparing an external composition for skin according to claim 1 wherein said R2 has 15 to 25 carbon atoms.
18. A method for preparing an external composition for skin according to claim 17 wherein said R2 has a structure represented by any one of the following formulae a to c:
Figure US06348201-20020219-C00009
19. A method for preparing an external composition for skin according the claim 13 wherein said R3 is a substituted or unsubstituted straight alkyl group having 10 to 20 carbon atoms.
20. A method for preparing an external composition for skin according to claim 17 wherein said R3 is a straight alkyl group having 12 carbon atoms.
21. A method for preparing an external composition for skin according to claim 7 which further comprises the step of mixing said extract with at least one of whitening agent, surfactant, dye, perfumery, aseptic agent, pigment, mildewproof agent, antioxidant, UV absorber, infrared absorber, fluorescent material, metal ion blocker, binder, filler, antiphlogistic, circulation accelerator, cell activator and antibiotic.
22. A method for preparing an external composition for skin according to claim 13 wherein said R1 has a structure represented by any one of the following formulae A to D:
Figure US06348201-20020219-C00010
and said R2 has a structure represented by any one of the following formulae a to c:
Figure US06348201-20020219-C00011
23. A method of using the external composition for skin prepared by the method according to claim 7 as a toilet soap, shampoo, cleansing foam, rinse, eye cream, eye shadow, cream or milky lotion, toilet lotion, perfume, face powder, facial oil, hair-care cosmetics, hair dye, jelly fragrance, powder, pack, shaving cream, shaving lotion, suntan oil, anti-suntan oil, suntan lotion, sun-screening lotion, suntan cream, sun-screening cream, foundation, powdery fragrance, cheek rouge, mascara, eyebrow pencil, nail cream, nail enamel, nail enamel remover, hair cleaner, bath cosmetics, lipstick, lip cream, eyeliner, toothpaste, deodorant agent eau de cologne, hair tonic, hair restorer, ointment, wet pack, medicated lip cream or anti-atopic agent, comprising
applying said composition to skin, hair or fingernails.
US09/084,394 1997-05-30 1998-05-27 External composition for skin comprising sphingoglycolipid Expired - Lifetime US6348201B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/012,510 US6514744B2 (en) 1997-05-30 2001-12-12 External compositions for skin comprising sphingoglycolipid

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
JP14176897 1997-05-30
JP9-141771 1997-05-30
JP141770/1997 1997-05-30
JP9-141768 1997-05-30
JP14177097A JPH10327853A (en) 1997-05-30 1997-05-30 Culture medium
JP14176997 1997-05-30
JP9141771A JPH10330273A (en) 1997-05-30 1997-05-30 Production of preparation for external use for skin
JP141769/1997 1997-05-30
JP9-141770 1997-05-30
JP141768/1997 1997-05-30
JP9-141769 1997-05-30
JP141771/1997 1997-05-30
JP00996398A JP3483448B2 (en) 1997-05-30 1998-01-21 External preparation for skin
JP10-00963 1998-01-21
JP009963/1998 1998-01-21
JP6174998A JP3504137B2 (en) 1997-05-30 1998-03-12 Sphingomonas spp.
JP10-061749 1998-03-12
JP061749/1998 1998-03-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/012,510 Division US6514744B2 (en) 1997-05-30 2001-12-12 External compositions for skin comprising sphingoglycolipid

Publications (2)

Publication Number Publication Date
US20020006414A1 US20020006414A1 (en) 2002-01-17
US6348201B2 true US6348201B2 (en) 2002-02-19

Family

ID=27548238

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/084,394 Expired - Lifetime US6348201B2 (en) 1997-05-30 1998-05-27 External composition for skin comprising sphingoglycolipid
US10/012,510 Expired - Fee Related US6514744B2 (en) 1997-05-30 2001-12-12 External compositions for skin comprising sphingoglycolipid

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/012,510 Expired - Fee Related US6514744B2 (en) 1997-05-30 2001-12-12 External compositions for skin comprising sphingoglycolipid

Country Status (4)

Country Link
US (2) US6348201B2 (en)
EP (1) EP0887070B1 (en)
CA (1) CA2239295C (en)
DE (1) DE69828221T2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514744B2 (en) * 1997-05-30 2003-02-04 Kibun Food Chemifa Co., Ltd. External compositions for skin comprising sphingoglycolipid
US20040001797A1 (en) * 2002-06-21 2004-01-01 Abel Saud Antimicrobial compositions, products and methods employing same
US20040138177A1 (en) * 2001-03-12 2004-07-15 Park Chang Seo Therapeutic composition for broad spectrum dermal disease
US20040219177A1 (en) * 2003-04-29 2004-11-04 Jacobs Randy J. Depleted skin barrier replenishing skin creams composition and method of application
WO2005030161A1 (en) * 2003-10-02 2005-04-07 Doosan Corporation Composition for protecting skin
US20050180988A1 (en) * 2004-02-13 2005-08-18 Chee-Keung Chung External preparation for skin containing oleaginous substances extracted from Ganoderma lucidum and method of using the same
US20060269524A1 (en) * 2004-02-19 2006-11-30 Kibun Food Chemifa Co., Ltd. Composition for nkt cell activation
US20110039801A1 (en) * 2006-10-16 2011-02-17 Lion Corporation Nk1 receptor antagonist composition
CN109234180A (en) * 2017-07-10 2019-01-18 伽蓝(集团)股份有限公司 Sphingol single-cell, its extracellular products and its preparation method and application
KR102402933B1 (en) * 2022-01-03 2022-05-30 한국콜마주식회사 Hair cleansing composition comprising sphingomonas ferment extract
US11369552B1 (en) 2020-09-11 2022-06-28 Elena Yurievna Komarova Aqueous nail polish remover

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4099267B2 (en) * 1998-08-07 2008-06-11 株式会社紀文フードケミファ Emulsifier and emulsified composition
US6239088B1 (en) * 1999-03-19 2001-05-29 Color Access, Inc. Nonirritating cleansing composition
US6261566B1 (en) 1999-10-22 2001-07-17 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Cosmetic compositions containing mulberry extract and retinoids
KR20010102550A (en) * 2000-01-11 2001-11-15 겜마 아키라 Microgels and external preparations containing the same
JP4173944B2 (en) * 2000-06-29 2008-10-29 株式会社紀文フードケミファ Glycosphingolipid
KR100978348B1 (en) 2001-08-31 2010-08-26 케라텍 리미티드 The production of biopolymer film, fibre, foam and adhesive materials from soluble s-sulfonated keratin derivatives
TW200413024A (en) * 2001-12-28 2004-08-01 Neochemir Inc Carbon dioxide external composition and method for producing the same
US7630403B2 (en) * 2002-03-08 2009-12-08 Texas Instruments Incorporated MAC aggregation frame with MSDU and fragment of MSDU
CN100506294C (en) * 2002-06-10 2009-07-01 凯瑞泰克有限公司 Orthopaedic materials derived from keratin
CA2506847A1 (en) * 2002-11-28 2004-06-10 Keratec Limited Personal care formulations containing keratin
DE10301907A1 (en) * 2003-01-17 2004-08-05 Westfälische Wilhelms-Universität Münster Process for producing an exopolymer and its use
FR2855049B1 (en) * 2003-05-19 2006-07-21 Oreal COMPOSITION COMPRISING A 6-HYDROXY SPHINGENINE CERAMIDE PRECURSOR AND A 6-HYDROXYLASE PATH ACTIVATOR FOR USE IN ENHANCING THE BARRIER FUNCTION OF THE SKIN
FR2855048B1 (en) * 2003-05-19 2006-07-21 Oreal COMPOSITION COMPRISING A PHYTOSPHINGOSIN-BASED CERAMIDE PRECURSOR AND AN ACTIVATOR OF THE 4-HYDROXYLASE PATHWAY, USE FOR ENHANCING THE BARRIER FUNCTION OF THE SKIN
WO2005028560A1 (en) * 2003-09-19 2005-03-31 Keratec Limited Composite materials containing keratin
CN1997408A (en) * 2003-12-19 2007-07-11 凯瑞泰克有限公司 Wound care products containing keratin
US7579317B2 (en) * 2005-03-11 2009-08-25 Keratec, Ltd. Nutraceutical composition comprising soluble keratin or derivative thereof
US20070207097A1 (en) * 2006-02-21 2007-09-06 Kelly Robert J Treating hair or nails with internal wool lipids
CA2672069A1 (en) * 2006-12-06 2008-06-12 Keratec, Ltd. Bone void fillers and methods of making the same
CA2672529A1 (en) * 2006-12-11 2008-06-19 Keratec, Ltd. Porous keratin construct and method of making the same
US20080317826A1 (en) * 2007-05-24 2008-12-25 Robert James Kelly Porous keratin constructs, wound healing assemblies and methods using the same
JP5916438B2 (en) * 2012-03-01 2016-05-11 三菱鉛筆株式会社 Liquid cosmetics
CN105380845A (en) * 2015-11-24 2016-03-09 张娟 Tremella fuciformis vanishing cream
KR102242196B1 (en) 2018-12-10 2021-04-20 주식회사 엠디헬스케어 Nanovesicles derived from Sphingomonas bacteria and Use thereof
KR20230035590A (en) * 2020-06-30 2023-03-14 아미리스 인코퍼레이티드 Metal Oxide Sunscreen Formulation
US20240024379A1 (en) * 2020-12-18 2024-01-25 L’Oreal Extract of bacteria of the genus sphingomonas
FR3117776B1 (en) * 2020-12-18 2024-03-08 Oreal Extract of bacteria from the genus Sphingomonas
KR102599728B1 (en) * 2021-04-01 2023-11-08 주식회사 지놈앤컴퍼니 Novel strain of sphingomonas paucimobilis and use thereof

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0150712A2 (en) 1984-01-04 1985-08-07 Bioiberica, S.A. Method for the obtention of a glycosphingolipid complex
JPS61286307A (en) 1985-06-13 1986-12-16 Kanebo Ltd Skin cosmetic
JPS62187404A (en) * 1986-02-12 1987-08-15 Pola Chem Ind Inc Cosmetic
JPH01242690A (en) 1988-03-24 1989-09-27 Pola Chem Ind Inc Cholesteric liquid crystal composition and cosmetic material containing the same
JPH0248520A (en) 1988-08-10 1990-02-19 Pola Chem Ind Inc Cleaning agent
JPH04159203A (en) 1990-09-19 1992-06-02 Pola Chem Ind Inc External preparation for skin
FR2679770A1 (en) 1991-08-01 1993-02-05 Oreal Cationic dispersions for treatment of the hair or skin based on ceramides and/or glycoceramides, cosmetic compositions containing them and their cosmetic applications
JPH0539485A (en) 1991-08-02 1993-02-19 Kose Corp Liquid crystal composition and cosmetic containing the same
JPH068007A (en) 1992-06-23 1994-01-18 Tsugami Corp Rotary guide bush drive device
EP0587288A1 (en) 1992-07-24 1994-03-16 Unilever Plc Cosmetic composition containing a lipid and a hydroxy or ketacarboxylic acid
JPH07133217A (en) 1993-11-08 1995-05-23 Noevir Co Ltd External agent for skin
FR2718960A1 (en) 1994-04-22 1995-10-27 Oreal Compositions for the treatment and protection of hair, based on ceramide and polymers with cationic groups.
JPH07285827A (en) 1994-04-15 1995-10-31 Noevir Co Ltd External preparation for skin
EP0699430A1 (en) 1994-08-02 1996-03-06 L'oreal Method of hair treatment using amides containing fatty chains and steam
WO1997015274A1 (en) 1995-10-23 1997-05-01 L'oreal Keratin fibre treatment composition including at least one setting polymer and at least one ceramide-type compound, and methods
US5672693A (en) * 1991-01-23 1997-09-30 Kabushikikaisha Kibun Shokuhin Glycosphingolipids

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0680007A (en) 1992-09-03 1994-03-22 Omron Corp Vehicle control device
NZ279855A (en) * 1994-02-04 1998-05-27 Bio Merieux Msrv1 and msrv2 pathogenic and/or infectious agents associated with ms, nucleic acids encoding them and diagnostic and therapeutic applications
CN1111635A (en) * 1994-05-10 1995-11-15 真炳攸 Sphingomyelin extracting and application in cosmetics and foods
DE69828221T2 (en) * 1997-05-30 2005-12-29 Kibun Food Chemifa Co., Ltd. External main care agent containing a sphingoglycolipid

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0150712A2 (en) 1984-01-04 1985-08-07 Bioiberica, S.A. Method for the obtention of a glycosphingolipid complex
JPS61286307A (en) 1985-06-13 1986-12-16 Kanebo Ltd Skin cosmetic
JPS62187404A (en) * 1986-02-12 1987-08-15 Pola Chem Ind Inc Cosmetic
JPH01242690A (en) 1988-03-24 1989-09-27 Pola Chem Ind Inc Cholesteric liquid crystal composition and cosmetic material containing the same
JPH0248520A (en) 1988-08-10 1990-02-19 Pola Chem Ind Inc Cleaning agent
JPH04159203A (en) 1990-09-19 1992-06-02 Pola Chem Ind Inc External preparation for skin
US5672693A (en) * 1991-01-23 1997-09-30 Kabushikikaisha Kibun Shokuhin Glycosphingolipids
FR2679770A1 (en) 1991-08-01 1993-02-05 Oreal Cationic dispersions for treatment of the hair or skin based on ceramides and/or glycoceramides, cosmetic compositions containing them and their cosmetic applications
JPH0539485A (en) 1991-08-02 1993-02-19 Kose Corp Liquid crystal composition and cosmetic containing the same
JPH068007A (en) 1992-06-23 1994-01-18 Tsugami Corp Rotary guide bush drive device
JPH06157283A (en) 1992-07-24 1994-06-03 Unilever Nv Use of cosmetics composition
EP0587288A1 (en) 1992-07-24 1994-03-16 Unilever Plc Cosmetic composition containing a lipid and a hydroxy or ketacarboxylic acid
JPH07133217A (en) 1993-11-08 1995-05-23 Noevir Co Ltd External agent for skin
JPH07285827A (en) 1994-04-15 1995-10-31 Noevir Co Ltd External preparation for skin
FR2718960A1 (en) 1994-04-22 1995-10-27 Oreal Compositions for the treatment and protection of hair, based on ceramide and polymers with cationic groups.
EP0699430A1 (en) 1994-08-02 1996-03-06 L'oreal Method of hair treatment using amides containing fatty chains and steam
WO1997015274A1 (en) 1995-10-23 1997-05-01 L'oreal Keratin fibre treatment composition including at least one setting polymer and at least one ceramide-type compound, and methods

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Abstract of Japanese Patent 06,145,189, May 1994.
Abstract of WIPO Patent 97-394191, Apr. 1997.
Kawahara, K., et al., "Isolation of an Unusual "Lipid A' Type Glycolipd from Pseudomonas Paucimobilis," Biochimica Et Biophysica Acta 712:571-575 (1982).
Yabuuchi, E., et al., "Flavobacterium Devorans ATCC 10829: A Strain of Pseudomonas Paucimobilis," J. Gen. Appl. Microbiol. 25:95-107 (1979).
Yabuuchi, E., et al., "Proposals of Sphingomonas paucimobilib gen. nov. and comb. nov., Sphingomonas parapaucimobilis sp. nov., Sphingomonas yanikuyae sp. nov., Sphingomonas adhaesiva sp. nov., Sphingomonas capsulate comb. nov., and Two Genospecies of the Genus Sphingomonas," Microbiol Immunol. 34-2:99-119 (1990).
Yamamoto, A., et al., "Isolation of a Novel Sphingoglycolipid Containing Glucuronic Acid and 2-Hydroxy Fatty Acid from Flavobacterium devorans ATCC 10829." J. Biochem 83:1213-1216 (1978).

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514744B2 (en) * 1997-05-30 2003-02-04 Kibun Food Chemifa Co., Ltd. External compositions for skin comprising sphingoglycolipid
US20040138177A1 (en) * 2001-03-12 2004-07-15 Park Chang Seo Therapeutic composition for broad spectrum dermal disease
US6964952B2 (en) * 2001-03-12 2005-11-15 Doosan Corporation Therapeutic composition for broad spectrum dermal disease
US20040001797A1 (en) * 2002-06-21 2004-01-01 Abel Saud Antimicrobial compositions, products and methods employing same
US20040219177A1 (en) * 2003-04-29 2004-11-04 Jacobs Randy J. Depleted skin barrier replenishing skin creams composition and method of application
US20090131717A1 (en) * 2003-10-02 2009-05-21 Changseo Park Composition for protecting skin
WO2005030161A1 (en) * 2003-10-02 2005-04-07 Doosan Corporation Composition for protecting skin
US20050180988A1 (en) * 2004-02-13 2005-08-18 Chee-Keung Chung External preparation for skin containing oleaginous substances extracted from Ganoderma lucidum and method of using the same
US7060286B2 (en) 2004-02-13 2006-06-13 Chee-Keung Chung External preparation for skin containing oleaginous substances extracted from Ganoderma lucidum
US20060269524A1 (en) * 2004-02-19 2006-11-30 Kibun Food Chemifa Co., Ltd. Composition for nkt cell activation
US20110039801A1 (en) * 2006-10-16 2011-02-17 Lion Corporation Nk1 receptor antagonist composition
US8426386B2 (en) * 2006-10-16 2013-04-23 Lion Corporation NK1 receptor antagonist composition
CN109234180A (en) * 2017-07-10 2019-01-18 伽蓝(集团)股份有限公司 Sphingol single-cell, its extracellular products and its preparation method and application
CN109234180B (en) * 2017-07-10 2022-10-14 伽蓝(集团)股份有限公司 Sphingomonas, extracellular products thereof, and preparation method and application thereof
US11369552B1 (en) 2020-09-11 2022-06-28 Elena Yurievna Komarova Aqueous nail polish remover
KR102402933B1 (en) * 2022-01-03 2022-05-30 한국콜마주식회사 Hair cleansing composition comprising sphingomonas ferment extract

Also Published As

Publication number Publication date
US6514744B2 (en) 2003-02-04
DE69828221D1 (en) 2005-01-27
US20020164351A1 (en) 2002-11-07
CA2239295C (en) 2010-03-09
CA2239295A1 (en) 1998-11-30
EP0887070B1 (en) 2004-12-22
EP0887070A1 (en) 1998-12-30
DE69828221T2 (en) 2005-12-29
US20020006414A1 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
US6348201B2 (en) External composition for skin comprising sphingoglycolipid
CN102112106B (en) Cosmetic composition for anti-aging of the skin comprising phaseolus radiatus seed extracts by fermentation and enzyme treatment
CA2279795C (en) Methods of making an emulsified composition
JP2005015348A (en) Skin cosmetic
US20100008878A1 (en) Propylene glycol hyaluronate, and skincare preparation for external use comprising same
JP2883835B2 (en) Extract from Catharanthus roseus seed, method for obtaining the same, and composition containing the same
EP1167374B1 (en) Glycosphingolipid
JP3483448B2 (en) External preparation for skin
US6710038B1 (en) Emulsification method using propylene glycol hyaluronate
JP3415104B2 (en) Hyaluronic acid propylene glycol ester and external preparation for skin using the same
DE60012866T2 (en) Propylene glycol hyaluronate and topical skin care product containing it
JP3504137B2 (en) Sphingomonas spp.
EP1110971B1 (en) Propylene glycol hyaluronate and agent for external use to skin using the same
JP2002293712A (en) Cosmetic
JPH10330273A (en) Production of preparation for external use for skin
JPH10316529A (en) Humectant
JP2021075537A (en) Topical skin agent
JP6718202B2 (en) Topical skin
CN114250156A (en) Culture solution of yeast, method for producing same, skin external preparation, and skin cosmetic
JP2020176065A (en) Skin external preparation
JPH0755886B2 (en) Cosmetics

Legal Events

Date Code Title Description
AS Assignment

Owner name: KIBUN FOOD CHEMIFA CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MURATA, KATSUMI;NOZAWA, TAKASHI;HARA, HISAKO;AND OTHERS;REEL/FRAME:009388/0512

Effective date: 19980707

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

REFU Refund

Free format text: REFUND - SURCHARGE, PETITION TO ACCEPT PYMT AFTER EXP, UNINTENTIONAL (ORIGINAL EVENT CODE: R2551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: KIKKOMAN BIOCHEMIFA COMPANY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FOODCHEMIFA CO., LTD.;REEL/FRAME:027064/0787

Effective date: 20110825

Owner name: FOODCHEMIFA CO., LTD., JAPAN

Free format text: CHANGE OF NAME;ASSIGNOR:KIBUN FOOD CHEMIFA CO., LTD.;REEL/FRAME:027064/0745

Effective date: 20090401

FPAY Fee payment

Year of fee payment: 12